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ABSTRACT 
 
Melanie Beth Weed: THE IMPACT OF EPIDERMAL GROWTH FACTOR 
RECEPTOR INHIBITION ON ENERGY HOMEOSTASIS 
 
(Under the direction of David W. Threadgill) 
 
 
As a result of the worldwide rise in obesity and obesity-related complications 
such as diabetes, stroke, and cardiovascular disease, understanding the mechanisms 
associated with this disease and determining treatment options is necessary.  A balance 
between food intake and energy expenditure, through a highly integrated multi-organ 
system, determines body weight regulation.  Signals relaying energy storage and satiety 
from the periphery are sent to the central nervous system (CNS) where they, along with 
other neuronal signals, are used to maintain this balance.  Accumulating evidence 
suggests signaling through the epidermal growth factor receptor (EGFR) is required for 
normal adipocyte development; therefore understanding how this signaling contributes to 
excess body fat mass is necessary to unravel the mechanisms associated with obesity.  
Our lab has previously shown that EGFR inhibition retards adipose deposition in a diet-
induced obesity (DIO) model.  To further delineate the role of EGFR in DIO, we 
performed two studies using pharmacological and genetic mouse models with either 
suppressed or conditionally deleted EGFR.  In the first study, wild-type male C57BL/6J 
mice were chronically exposed to a high-fat western diet (WD) with or without a small 
molecule inhibitor to the EGFR tyrosine kinase, AG1478.   In a separate experiment,
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mice homozygous for the Egfrwa2 mutation, a constitutionally impaired EGFR tyrosine 
kinase, and their control littermates were also challenged with this WD.  The second 
study aimed to understand the role of EGFR in energy homeostasis in DIO.  Mice with 
Egfr specifically deleted in peripheral tissues (intestines and adipocytes) and in the CNS 
using the Egfrtm1Dwt conditional allele and the Villin-Cre, aP2-Cre, and GFAP-Cre, 
transgenic lines, respectively, were chronically exposed to the WD.  Significantly less 
body weight and fat mass were observed in mice with EGFR inhibition, either 
pharmacologically with AG1478 or genetically in the Egfrwa2 and GFAP-Cre genetic 
lines.  Alterations in adipocyte size, adipocyte-specific factors, food intake, energy 
expenditure, and clinical parameters were also observed in these mice. We conclude that 
alterations in energy homeostasis account for this fat mass decrease.  These studies 
should aid in our understanding of the role of EGFR in appetite and metabolism and 
provide potential avenues for the treatment of obesity. 
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CHAPTER 1 
THE ROLE OF EGFR SIGNALING IN ADIPOSE DEPOSITION AND OBESITY 
Abstract 
Since the mid-1970s, the prevalence of overweight (BMI ≥ 25) and obesity (BMI 
≥ 30) has increased sharply for both adults and children.  Being overweight or obese 
increases the risk of many diseases and health conditions, including type-2 diabetes, 
hypertension, hyperglycemia, atherosclerosis, cancer, and stroke.  Obesity is caused by a 
higher energy intake than expenditure and results in increased fat mass due to an increase 
in preadipocyte proliferation and adipocyte differentiation. Accumulating evidence 
suggests signaling through the epidermal growth factor receptor (EGFR) is required for 
adipocyte development.  The EGFR, a member of the ERBB family, is expressed in a 
wide range of tissues and cell types that regulate a number of cellular processes such as 
proliferation, differentiation, motility, apoptosis, and survival.  We review here the 
current literature surrounding obesity prevalence, the makeup of adipose tissue, and the 
process of adipogenesis.   We then discuss how factors such as EGFR and its ligands 
influence adipogenesis and how the use of in vivo models can help elucidate EGFR 
signaling relating to adipose deposition.  We next review the current understanding of 
energy regulation in the body and how EGFR signaling may be involved.  Finally we 
discuss current therapies directed towards obesity and how an alternative obesity 
treatment may be to target EGFR. 
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ERBB family 
The epidermal growth factor receptor (EGFR), the prototypical member of the 
ERBB family, is expressed in a wide range of tissues and cell types that regulate a 
number of cellular processes such as proliferation, differentiation, motility, apoptosis, and 
survival (1-4).  This family consists of four members: EGFR (ERBB1), ERBB2, ERBB3, 
and ERBB4 that each contain an extracellular ligand binding domain, a transmembrane 
region, an intracellular tyrosine kinase domain, and a C terminus.  Upon binding of 
ligands to the extracellular domain, these members form homo or heterodimers that 
initiate autophosphorylation of tyrosine residues and signaling cascades (Figure 1).  Due 
to the absence of a recognized ligand to ERBB2 and the impaired tyrosine kinase domain 
of ERRB3, these ERBB receptors only function through heterodimerization with a 
second, ligand-binding or kinase-active ERBB receptor, respectively (3-7). 
Regulating the duration and potency of activation of these signaling cascades is a 
complex process, and ligand binding is an important aspect in this regulation.  The 
epidermal growth factor (EGF)-related ligands are produced as transmembrane 
precursors, activated by protease cleavage to form soluble growth factors.  The zinc-
dependent disintegrin-like and metalloproteinase-containing proteins (ADAMs) are the 
proteases that cleave EGF proligands (7, 8).  Three groups of EGFR ligands exist, based 
upon an EGF-like domain that determines receptor specificity.  The first group includes 
EGF, transforming growth factor-α (TGFA), and amphiregulin (AREG), which bind 
specifically to EGFR.  The second group includes betacellulin (BTC), heparin-binding 
EGF (HBEGF), and epiregulin (EREG), which can bind and activate EGFR and ERBB4.  
The third group is composed of four neuregulins (NRG1-4), which form two subgroups 
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based upon their binding to ERBB3 and ERBB4 (NRG1 and NRG2) or only ERBB4 
(NRG3 and NRG4) (7, 9, 10).  Therefore, ligand binding aids in controlling the formation 
of defined ERBB dimers through selective binding to their target receptor that influences 
which receptor tyrosine phosphorylation patterns and signaling pathways are activated 
throughout the body.  The mitogen-activated protein kinase (MAPK) pathway is a 
common target downstream of all receptors, as is the phosphatidylinositol-3-kinase 
(PI3K) pathway.  Signal downregulation for EGFR and other ERBB family members is 
through internalization and targeting to the endosomal compartment for degradation (7, 
11). 
Also aiding in the complexity of these signaling cascades is the transactivation of 
EGFR by G-protein coupled receptors (GPCRs), cytokine receptors, receptor tyrosine 
kinases, and oxidants.  GPCRs involved in transactivation include thrombin, angiotensin 
II, and α and β adrenergic receptors.  This transaction process occurs when stimuli 
increase the activity of metalloproteases (MMPs), which leads to ligand shedding and 
binding to ERBB receptors in either an autocrine or paracrine fashion and signaling 
cascades involved in proliferation, migration, or inhibition of apoptosis (12, 13).  Since 
EGFR signaling cascades are involved in proliferation and differentiation, they may also 
be involved in adipogenesis and therefore contribute to the development of obesity. 
Obesity prevalence and complications 
Since the mid-1970s, the prevalence of overweight (BMI ≥ 25) and obesity (BMI 
≥ 30) has increased sharply for both adults and children.  Results from the 2007-2008 
National Health and Nutrition Examination Survey (NHANES) indicate that in adults 
aged 20–74 years the prevalence of obesity has increased from 15.0% in 1976 to 33.8% 
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in 2008.  The NHANES study from 2003-2004 indicated that an estimated 17% of 
children and adolescents 2-19 years of age are overweight, with the prevalence of 
overweight increasing from 7.2 to 17% from 1976 through 2004 (14, 15).  Being 
overweight or obese increases the risk of many diseases and health conditions, including 
type-2 diabetes, hypertension, hyperglycemia, atherosclerosis, cancer, and stroke.  Also, 
childhood obesity is associated with a higher chance of premature death and disability in 
adulthood (16, 17).  Obese women show increased risk for postmenopausal breast cancer 
and obese breast cancer patients have a higher risk for large tumors, lymph node 
metastases, and death, compared to non-obese patients (18).  It has also been suggested 
that there is an increased risk of developing hepatocellular carcinoma due to increased 
lipid in the liver of the obese (19).  Due to these many health conditions, medical costs 
attributed to both overweight and obesity accounted for $114 billion dollars in 2008 (20).  
Obesity is just one of the factors associated with metabolic syndrome, which 
includes such symptoms as hypertension, insulin resistance, and hyperlipidemia.  This 
syndrome is associated with a state of low-grade systemic inflammation with levels of 
cytokines such as tumor necrosis factor-α (TNFA) and interleukin-6 (IL6) elevated in 
serum and adipose tissue as well as increased free fatty acid release (21-27).  Obesity is 
associated with disrupted signaling efficacy of adipokines such as leptin, adiponectin, 
resistin, plasminogen activator inhibitor-1 (PAI1), and insulin, and occurs when energy 
balance is disrupted.  Restoration of adipokine balance and responsiveness occurs with 
reduction in obesity (22, 28, 29).  Leptin is a 16 kD protein that is produced and secreted 
from white adipose tissue and signals the amount of adipose tissue mass to the central 
nervous system (CNS) for energy regulation (30).  Peripheral or central administration of 
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leptin has been shown to reduce body weight, food intake, and blood glucose levels in 
lean and obese mice with leptin deficiency; however, no effects are noted in another 
mouse model with a leptin receptor mutation.  To try and overcome this resistance, 
adipocytes secrete more leptin resulting in higher leptin levels (31).  Insulin works similar 
to leptin in that it inhibits feeding and increases energy expenditure.  As weight and body 
fat increases, so does insulin secretion to maintain normal glucose homeostasis.  Insulin 
resistance occurs if the pancreatic β-cell does not produce enough insulin leading to 
hyperglycemia and potentially producing type 2 diabetes.  Therefore in times of weight 
gain, leptin and insulin production are increased, and with weight loss production 
decreases (31-33).  Adiponectin is a 30 kD protein expressed and secreted at high levels 
in adipocytes.  Decreased levels are associated with a high BMI, insulin resistance, 
inflammation, increased levels of plasma lipids, and cardiovascular disease (34, 35). 
The increase in fat mass associated with overweight and obesity is related to a 
combination of (1) strong genetic and metabolic maintenance of energy stores; (2) the 
food environment that is available, usually leading to the over-consumption of calorie-
dense and nutrient-poor foods; and (3) increases in lack of physical activity due to 
technology.  Factors contributing to this obesogenic environment and the consequential 
toxic effects of overweight and obesity also include large portion sizes and visibility and 
accessibility of foods.  Diets high in fat are also known to quickly cause insulin resistance 
and signs of inflammation, which disrupts adipokine levels.  In genetic (i.e. ob/ob and 
Zucker fa/fa rat) and diet-induced obesity mouse models and in obese humans, a high-fat 
diet (HFD) is also known to reduce sympathetic nervous system activity and to reduce 
glucose transporter (GLUT)-2 and glucose-stimulated glucose tolerance (22, 31, 33, 36-
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38).  Another factor contributing to this obesogenic environment includes lack of 
physical activity, which along with a HFD are the primary environmental factors leading 
to increases in obesity (38, 39).  
Being overweight or obese may also lead to potential changes in susceptibility to 
environmental contaminants.  Since adipose tissue is mostly composed of lipids, it 
represents a major reservoir for many different lipophilic contaminants such as persistent 
organic pollutants (i.e., polychlorinated biphenyls or dioxins) (40, 41).  Consequently, 
individuals with a large amount of adipose tissue are likely exposed to elevated endocrine 
or physiological disruption.  These pollutants may alter the secretory function and 
metabolism of adipocytes and transcription factor activation in adipogenesis.  It has been 
further hypothesized that exposure to environmental contaminants prenatally may lead to 
obesity as adults (40-43).  For example, dioxins are environmental anti-estrogens and 
endocrine disruptors, are lipophilic, and are stored in fat.  Exposure of 3T3-L1 
preadipocytes to dioxins results in an impairment of adipose function by decreasing the 
activity of lipoprotein lipase, glucose transport, and accumulation of triglycerides, due to 
decreases in adipogenic transcription factors (44, 45).  The mechanism of dioxin’s toxic 
action involves the modulation of growth factor receptors and components of their signal 
transduction pathways.  This was observed in vivo in immature female rats exposed to 
dioxin at a dose of 2 µg of dioxin/kg.  This dose decreased body weight gain and adipose 
tissue weight in the immature rats by decreasing the activities of signaling pathways 
downstream of a receptor tyrosine kinase (44, 46, 47). 
Because of the toxic obesogenic environment (both internal and external) that we 
are exposed to, the adverse health conditions that occur, high health care costs, and 
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exposure to lipophilic environmental contaminants, a better understanding of the 
mechanisms associated with this disease and identifying potential therapeutics are 
necessary.  In order to understand these mechanisms behind obesity, we first need to 
understand adipose biology and the steps in adipogenesis. 
Adipose tissue biology 
Adipose tissue is composed of many different cell types at varying staging of 
differentiation.  Adipocytes, stromal-vascular cells, blood vessels, nerves, and lymph 
nodes make up adipose tissue (48, 49).  Preadipocytes contain no lipid in their cytoplasm 
but as they mature they accumulate more lipid until they are fully differentiated and their 
cytoplasm is full.  In a population of mature adipocytes, there are various sizes.  When 
these cells grow, as in obesity, the heterogeneity of the sizes decreases (48, 49).  Blood 
supply to the adipose tissue provides for the delivery of metabolic products and removal 
of wastes.  With obesity, the supply of blood to adipose tissue can be 15-30% of the total 
cardiac output, leading potentially to high blood pressure and heart failure (48).  Adipose 
tissue surrounding lymph nodes demonstrates a connection with the immune system since 
this organ can secrete inflammatory factors.  Also, adipose tissue is innervated by the 
sympathetic nervous system and by sensory neurons regulating such important processes 
as lipolysis (48).  The different adipose depots in the body possess regional differences in 
growth and cellularity as well as metabolism.  In looking at in vitro and in vivo models, it 
was found that different adipose regions develop at different rates, possibly due to the 
local expression of factors, the cell populations present, or innervation, and respond to 
stimuli such as insulin differently.  For example, epididymal depots show a higher blood 
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flow, growth modality, and innervation than inguinal depots, however the inguinal depot 
shows a higher proliferative capacity (48, 50). 
White adipose tissue (WAT) stores energy as triglycerides and excess storage 
leads to obesity, with increased fat volume as a marker.  The normal values of percent 
body fat for humans range from 9 to 18% in males and 14 to 28% in females.  In obesity, 
percentages of 22% and 32% (and higher) in males and females, respectively, can be 
observed (48).  Mild obesity results in hypertrophy of the adipocytes while severe obesity 
leads to both hyperplasia and hypertrophy, with the latter showing the poorest prognosis 
for weight loss (48, 49).  In humans and mice, WAT is mostly absent a birth, developing 
postnatally, while brown adipose tissue (BAT) is developed during fetal life and found 
largely in the interscapular region.  Mature WAT adipocytes contain single fat droplets 
within the cells while mature BAT adipocytes show a multiocular distribution of the fat 
droplets (50). These two adipose stores show functional differences with WAT storing 
extra nutrients in times of excess and releasing these nutrients in times of scarcity, while 
BAT is involved in non-shivering thermogenesis through the uncoupling of the 
mitochondrial β-oxidation pathway and wasting energy as heat (51).  Recent data has also 
shown that brown and white adipocytes are present together in the same depots and may 
interconvert depending on energy needs, genetic background, and degree of sympathetic 
stimulation (52-54).  It has been shown that BAT plays an essential role in energy 
balance and that its activity influences body weight in rodents, while it has been thought 
that humans do not possess enough BAT to impact energy in the body.   However, recent 
evidence has shown that adult humans clearly have depots of metabolically active BAT, 
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suggesting that it may play a significant role in the regulation of body weight (49, 51, 
55). 
Adipogenesis 
Obesity is a result of increased fat mass due to higher energy intake than 
expenditure and is associated with an increase in preadipocyte proliferation and adipocyte 
differentiation.  Proliferation leads to an increase in preadipocytes while differentiation is 
the transition of these cells from undifferentiated fibroblast-like cells to mature lipid-
filled fat cells (35, 48).  Most of our understanding of adipogenesis is through in vitro cell 
culture systems.  The 3T3-L1 cell line is one such system, which is already committed to 
the adipogenic pathway and is used to study adipogenesis.  When these preadipocytes 
undergo growth arrest and are treated with a combination of isobutylmethylxanthine, 
dexamethasone, and insulin (MDI), they start to produce a rounded phenotype.  Within 
two to three days of this treatment, they begin to differentiate and accumulate lipids 
intracellularly in the form of lipid droplets (35, 48, 56).   
Once preadipocytes reach confluence and differentiation is induced, terminal 
differentiation occurs through the induction of transcription factors, expression of 
adipogenic genes, and lipid accumulation (57, 58) (Figure 2).  Transcription factor 
CAAT/Enhancer Binding Protein (C/EBP) is found in preadipocytes as β, α, and 
δ isoforms.  C/EBPB is part of the basic leucine zipper family and is one of the first 
transcription factors induced after the induction of differentiation.  It promotes the 
transcription of a number of other adipogenic genes such as peroxisome proliferator-
activated receptor -γ (PPARG) and C/EBPA (35, 56-59).  PPARG is a nuclear hormone 
receptor existing as two isoforms, with PPARG2 being most abundant in adipocytes.  It is 
expressed in small amounts in preadipocytes and its synthesis increases during 
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differentiation (49, 54, 60).  C/EBPA is essential for the development of mature 
adipocytes in vitro and in vivo and activates several adipocyte-specific genes such as 
GLUT4, fatty acid synthetase, fatty acid binding protein, leptin, adiponectin, and 
uncoupling proteins (49, 56, 58, 59).  Inhibition of C/EBPA in 3T3-L1 cells leads to 
decreased lipid accumulation and expression of fat-specific markers, supported by the 
fact that mice with a targeted disruption of C/EBPA show reduced brown and white 
adipose mass (49).  It is thought that retention of the adipocyte phenotype is through the 
interaction between C/EBPA and PPARG and that PPARG is required for adipose 
development given that PPARG-null pups lack adipose tissue and do not survive (49, 54). 
Factors Modulating Adipogenesis 
Hormones, growth factors, and cytokines regulate adipogenesis, with some of 
these signals stimulating and others inhibiting this process.  For development, cells need 
to balance their growth as well as their differentiation.  A reversible growth arrest must 
occur in the G1 phase of the cell cycle before preadipocytes can commit to differentiation 
and respond to signals for terminal differentiation.  Therefore, factors that initiate growth 
may prevent this arrest and inhibit adipogenesis (35).  Terminal differentiation is 
characterized by an irreversible loss of proliferative capacity resulting in the decrease of 
growth regulating genes (35, 61).  Peptides, such as growth factors EGF, HBEGF, 
insulin-like growth factor-1 (IGF1), and platelet-derived growth factor (PDGF), stimulate 
cell growth and block preadipocyte differentiation (60-63).  This has been shown in vitro 
in 3T3-L1 and primary rat preadipocytes and in vivo where administration of EGF or 
HBEGF decreases the development of adipose tissue.  The administration of MDI 
however blocks increases in EGF so differentiation can occur (46, 63, 64).   
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Since it is known that growth arrest is necessary for adipogenesis to proceed, it is 
assumed that the signaling cascades induced by cytokines and growth factors affect the 
activity of transcription factors needed for the adipocyte phenotype.  It is thought that this 
activity is mediated through the activation of the MAPK signaling pathway, by 
phosphorylating PPARG on its MAPK consensus sites (54, 62).  This MAPK-mediated 
phosphorylation of PPARG then leads to blocking of transcriptional activity necessary 
for differentiation, due to ligands having a lower affinity for the phosphorylated form of 
PPARG.  This was shown in transcription reporter assays using 3T3-L1 preadipocytes 
where activated MAPK, through growth factor signaling, led to a suppression of PPARG 
transcriptional activity (54, 62).  There is also evidence that EGFR signaling via the 
MAPK pathway may inhibit adipogenesis through expression of Myc.  It has been shown 
that expression of Myc in 3T3-L1 preadipocytes inhibits differentiation as well as 
preventing normal C/EBPA induction (61).  Cytokines such as TNFA, IL1 and IL6 also 
inhibit adipogenesis.  Treatment of 3T3-L1 preadipocytes with TNFA or C3H10T1/2 
cells with HBEGF downregulates genes associated with the mature adipocyte phenotype 
such as PPARG, GLUT-4 and C/EBPA.  TNFA can also activate the MAPK pathway and 
by blocking this pathway with an inhibitor in vitro, TNFA’s effects on adipocyte 
differentiation are abolished (54, 60, 62, 65).    
It is also shown that EGF has lipogenic and lipolytic effects based on when and 
how much is available (Figure 3).  In a serum-free 3T3-L1 system, IGF1 only in 
combination with EGF can stimulate differentiation after growth arrest similar to that 
with insulin alone, showing the EGF supports cellular grow (66, 67).  As stated 
previously, since EGFR is mitogenic, it may prevent the growth arrest needed for 
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differentiation to proceed and therefore its signaling activity would be suppressed before 
differentiation can occur.  Increased amounts of EGF have been shown to increase 
adiposity in mature female mice and in 3T3-L1 mature adipocytes suggesting a lipogenic 
effect of this ligand, due in part to an increase in triglyceride synthesis (68).  This effect 
is inhibited following treatment of these animals with either anti-EGF or by removing the 
submandibular gland from the mouse, which produces large amounts of EGF.  Also noted 
in these studies is a decrease in acyl-coA synthase and lipoprotein lipase mRNA, which 
are part of the triglyceride synthesis pathway (68-70).  The effect of EGF inhibition is 
thought to be specific to adipocytes since fat pad weights were decreased in these mice 
while other organs weights were not changed.  This lipogenic effect is only noted, 
however, in adult mice or in mature adipocytes, where differentiation has already 
occurred (71).  When neonatal mice were injected with EGF for 10 days, their body 
weights decreased as well as their inguinal fat pad weights and triglyceride synthesis, 
with larger lipolytic effects seen upon increasing concentrations of EGF (71).  In 3T3-L1 
preadipocytes, very low concentrations of EGF have been shown to stimulate 
extracellular regulatory kinase (ERK) and p38 MAPK activity through dimer formation 
of EGFR and/or ERBB2, showing that ERK is involved in preadipocyte proliferation 
(72).  This is also observed with ERK1-/- mice where low adiposity and adipocyte number 
was noted versus wild-type mice on a HFD (73).  Also in a study in young mice carrying 
the dominant negative or antimorphic allele EgfrWa5 fed a normal chow diet, a significant 
reduction in percent body fat compared to their control littermates was noted, suggesting 
that reduced EGFR signaling is growth inhibitory to mature adipocytes (74).  This would 
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be expected given that MAPK signaling is thought to inhibit differentiation and therefore 
smaller cells or preadipocytes would be prevalent (71-74). 
A possible explanation for these controversial effects of EGF in adipogenesis 
could be EGFR’s interaction with ERBB2 in adipocytes.  ERBB2 expression is also 
found in 3T3-L1 preadipocytes with EGFR.  It can be recalled that ERBB2 does not have 
a ligand binding domain and therefore heterodimerizes with other ERBB members, with 
EGFR being the preferred partner (72, 75).  ERBB2’s expression is found to increase 
during the proliferation and growth arrest phases of adipogenesis; however, addition of 
MDI and progression through differentiation leads to a decrease in expression, similar to 
EGFR (72).  Also, when serum-starved 3T3-L1 preadipocytes were given EGF, an 
increase in ERBB2 activation was noted showing that EGF could activate ERBB2, 
through this heterodimerization with EGFR (72, 75).  However when these cells were 
given a ligand specific to ERBB3 and ERRB4, no increase in phosphorylation of either 
EGFR or ERRB2 was observed, showing dependency on EGFR (67). 
In vivo models 
Many mouse models of obesity exist to examine obesity and these models have 
been used successfully to study human obesity.  Common mechanisms between these 
models and human obesity imply that similar biochemical changes exist between 
mammalian species in energy homeostasis (32).  Obesity in experimental animals is 
associated with central obesity, insulin resistance, hypertriglyceridemia, 
hyperinsulinemia, hyperleptinemia, and impaired glucose tolerance, similar to humans 
eating high-fat diets (31, 38).  C57BL/6J (B6) mice fed a HFD are one of the most 
commonly used mouse models for diet-induced obesity (DIO) (37, 76).  B6 mice develop 
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hyperleptinemia, with peripheral leptin administration decreasing feeding until they 
become resistant after 16 days on a HFD (31).  This apparent resistance phenomenon is 
also observed in obese humans who also have high plasma leptin levels.  They do not 
decrease food intake with exogenous leptin administration, which also does not affect 
weight loss (31, 33, 37).  However, when fed a normal or low-fat diet (LFD), B6 mice 
remain lean and physiologically normal.  Although these mice also have a higher feeding 
efficiency than other strains when challenged by a HFD, they also show increased 
activity levels relative to other leaner strains (36).   Despite the fact that there is variation 
in the degree of adiposity among B6 mice even when they are maintained under similar 
conditions, this mouse model recapitulates many characteristics of the obesity phenotype 
in humans who also show varied adiposity (77).  
Genetic models of obesity also exist and include the Zucker fa/fa rat and the 
db/db, ob/ob, and M16 mice.  The fa/fa rat has a missense mutation in the leptin receptor 
gene, becoming obese due to an inability to respond to high leptin levels.  The db/db 
mouse is similar to the fa/fa rat in that it also has a leptin receptor mutation, which 
accounts for its obesity phenotype.  This db/db mouse model helped to predict a receptor 
for a circulating factor, namely leptin (78, 79).  The ob/ob mouse however is obese due to 
a mutation in the leptin gene, preventing production of a functional protein, and leptin 
was discovered because of this model (80).   With this mouse model, injection of leptin 
prevents obesity by regulating feeding through the leptin receptor (79).  Since obesity and 
diabetes are both effected by environmental and genetic factors, the M16 polygenic obese 
mouse model was produced as an outbred animal model of early onset polygenic obesity 
and diabetes.  These mice were selected for a large weight gain over 27 generations to 
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produce mice that are larger and have increased body fat, adipocytes, and organ weights 
when compared to a non-selected control line.  As with the B6 DIO model, these genetic 
models also show hyperleptinemia, hyperphagia, hyperglycemia, and hyperinsulinemia 
similar to human obesity (16, 78, 79). 
In order to dissect the role of EGFR in obesity, in vivo models exist that alter gene 
activity constitutionally (Table 1).  Null mutations of EGFR have also been studied and 
they result in varying phenotypes depending on genetic background.  These mice show a 
number of organ and embryonic abnormalities and die at different stages of 
embryogenesis or postnatally, dependent on genetic background (81, 82).  The waved-2 
(Egfrwa2) hypomorphic allele has a single nucleotide alteration that results in the 
substitution of a glycine for a valine in the highly conserved tyrosine kinase domain of 
EGFR (1).   This results in a reduced rate of internalization of EGFR and up to 90% 
reduction in EGFR activity in mice homozygous for the mutation.  Egfrwa2 homozygous 
mice are healthy and show a mild wavy coat phenotype, curly whiskers, and some 
endocrine and reproductive disorders including enlarged and thickened aortic valves and 
small mammary glands, while those heterozygous for the mutation show no abnormalities 
(1, 74). The wa-1 mutation (Tgfawa1) is a mutation of the Tgfa locus.  Mice homozygous 
for the Tgfawa1 mutation are slightly smaller than their control littermates and similar to 
the Egfrwa2 phenotype, Tgfawa1 mice show a wavy coat and whiskers (83, 84).  EgfrDsk5 is 
a hypermorphic allele of Egfr with a T to A transversion causing a missense mutation and 
a Leu863Gln substitution in the tyrosine kinase domain.  This is a gain-of-function 
mutation that causes an increase in tyrosine kinase activity and a decrease in receptor 
levels in vivo (85).  In mice homo or heterozygous for the EgfrDsk5 mutation, abnormal 
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skin pigmentation in the footpads and in the first digit are observed as is a wavy coat, a 
thicker epidermis, and increased nail length (85).  The waved-5 (EgfrWa5) dominant 
negative allele houses a single point mutation causing a missense mutation in exon 21.  
This mutation causing an aspartic acid to glycine change at amino acid residue 833 and 
altered tyrosine kinase function (74, 86).  Phenotypes for the EgfrWa5 mutation include 
peri and prenatal lethality in fetal growth and development, with embryos living longer 
than embryonic day 12.5 dying before or shortly after birth.  Wavy hair, curly whiskers, 
corneal scarring, and eyelids open at birth are other features of mice heterozygous for the 
EgfrWa5 mutant allele, similar to mice with the Egfrwa2 and EgfrDsk5 mutations (74, 86). 
Other model systems conditionally delete Egfr in specific cell types to study 
EGFR signaling, using Cre recombinase.  Cre recombinase is an enzyme derived from 
the bacteriophage P1 that specifically recognizes loxP sites.  Cre has been shown to 
effectively mediate the excision of DNA located between the loxP sites (87).  After this 
excision, the DNA ends recombine leaving a single loxP site in place of the intervening 
sequence.  Cre recombinase can be expressed under the control of different promoters 
such as the human glial fibrillary acidic protein (Gfap) promoter in the CNS, affecting 
astrocytes, oligodendroglia, and some neurons or under the fatty acid binding protein 
(ap2) promoter expressed highly in differentiated adipocytes as well as macrophages (88, 
89).  When the Cre system is combined with a loxP-flanked Egfr allele, EGFR should be 
excised in cells expressing the Cre recombinase, therefore producing mice where effects 
of EGFR deficiency can be investigated in specific cell types.   
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Energy Homeostasis 
Energy homeostasis within the body is based on a balance between energy intake 
and expenditure.  Obesity results from taking in more calories than required for this 
homeostasis.  Energy balance depends on the regulation of two principal systems.  First is 
the peripheral system that senses satiety and energy balance throughout the body and 
sends that information to the CNS.  Second is the CNS itself, which takes these signals 
along with other neuronal signals for food intake and energy and uses them to regulate 
homeostasis (90, 91).  The peripheral signals come from the adipose tissue, 
gastrointestinal tract, and other organs via fibers that innervate the nucleus tractus 
solitarius which then send afferent fibers to the hypothalamus and other regions (30). 
Body adiposity is regulated by an endocrine “adiposity” negative feedback loop 
involving insulin and leptin.  Both hormones function in a negative feedback manner to 
reduce food intake while increasing energy expenditure via actions on target neurons 
found in the arcuate nucleus (ARC) of the hypothalamus (Figure 4). Such neurons 
express receptors for insulin and leptin, respond directly to these hormones, and project 
to key brain areas involved in energy homeostasis, including the paraventricular nucleus 
and the lateral hypothalamic area (32, 91).  
Two key sets of neurons that are important for conveying appetite and energy 
signals are found in the ARC.  One set synthesizes orexigenic neuropeptides agouti-
related protein (AGRP) and neuropeptide Y (NPY), which stimulate food intake and 
decrease energy expenditure throughout the body (30).  Ablation of these neurons results 
in severe anorexia, while over activity results in obesity.  Insulin and leptin reduce the 
expression of these orexigenic neuropeptides (30, 32).  The other set of neurons 
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synthesize α-melanocyte-stimulation hormone (MSHA), derived from the pro-
opiomelanocortin (POMC) precursor molecule, and cocaine- and amphetamine-regulated 
transcript (CART) anorexigenic neuropeptides and they reduce food intake and increase 
energy expenditure when stimulated (32).  Mutations in the POMC gene lead to profound 
obesity and insulin and leptin induce the expression of these anorexigenic neuropeptides 
(30, 92).  MSHA binds to its melanocortin receptors (MC3 and MC4) in the brain to elicit 
a response.  In mice lacking the MC4 receptor, hyperphagia and obesity occurs, showing 
that these receptors are necessary to reduce food intake.  Importantly, this has also been 
noted in humans with mutations in the MC4 receptor (31, 92, 93).   
Other peptides that aid in the regulation of energy homeostasis include 
cholecystokinin (CCK), ghrelin, and peptide YY (PYY).  CCK is released upon eating 
and can decrease food intake in rodents by decreasing NPY levels (78).  Ghrelin is a 
gastric peptide, also produced in the hypothalamus, that possesses orexigenic properties 
through NPY and AGRP stimulation in the brain to stimulate food intake and appetite 
(78).  PYY is released by cells in the intestines in proportion to food ingested to stimulate 
POMC neurons in the ARC and inhibit feeding (30). 
It has been hypothesized that fatty acid metabolic pathways contribute to the 
regulation of energy balance and homeostasis within the hypothalamus and in the 
periphery.  During times of energy excess, lipolysis of triglycerides is decreased and 
during times of energy need lipolysis is increased (92). The regulation of this process in 
the hypothalamus occurs in response to different stimuli such as diet, insulin, and 
glucose.  It has been demonstrated that enzymes of fatty acid metabolic pathways are 
highly expressed in hypothalamic neurons involved in regulating feeding behavior (94).   
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Peripheral tissues such as WAT and BAT are also involved in this energy 
homeostasis.  Both tissues are innervated by the sympathetic nervous system and possess 
adrenergic receptors, a large family of GPCRs that couple to members of the 
heterotrimeric G proteins to activate adenylyl cyclase and cAMP-dependent protein 
kinase A (PKA).  PKA then phosphorylates hormone sensitive lipase, which acts upon 
proteins surrounding the lipid droplet for increased access and lipid breakdown (95, 96).  
Signaling through PKA has been shown to protect mice from diet-induced obesity, 
insulin resistance, and dyslipidemia when fed a high-fat diet by increasing lipolysis (97).  
This is shown in mice with an RIIbeta mutation.  Since PKA is composed of two 
regulatory subunits and two catalytic subunits, this RIIbeta mutation is compensated by 
an increase in the RIα regulatory subunit, which is more sensitive to cAMP activation and 
results in a net increase in basal PKA activity (97, 98).   In times of energy need, the 
sympathetic nervous system stimulates GPCRs, namely the β-adrenergic (ARB) 
receptors, for lipolysis in WAT and non-shivering thermogenesis in BAT (95).  ARB3 
can also activate the MAPK pathway to account for 15 to 25% of total lipolysis in WAT 
in rodents.  ARA receptors on the other hand are antilipolytic through the inhibition of 
cAMP production (95, 96, 99).  One study using 3T3-L1 preadipocytes showed that 
ARB3 works through EGFR and Src to activate the MAPK pathway and that inhibition of 
EGFR with tyrosine kinase inhibitor (TKI) AG1478 inhibits ERK activation and partially 
blocks lipolysis by an ARB3 agonist (100, 101).   
All members of the ERBB family are expressed in the developing and adult 
human brains.  TGFA and EGFR are expressed in a similar pattern in the brain, with both 
being found in neurons and astrocytes and EGFR also in oligodendrocytes (10, 102, 103).  
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TGFA is considered the major ligand for EGFR in the CNS and its mRNA is found 
throughout the brain, being especially high in the hypothalamus, while EGF expression is 
lower in the hypothalamus and cerebellum.  TGFA, EGF, and HBEGF have important 
roles in the development of the nervous system, from the proliferation of neural 
progenitor cells to the differentiation of precursor neuronal and glial cells (10).  EGF is 
found in body fluids such as saliva, blood, and cerebrospinal fluid and adult levels in the 
mice are achieved by four months (102).  EGF can act via paracrine, autocrine, or 
endocrine mechanisms within the CNS and has been shown to work directly in the CNS 
to suppress food intake.  In sheep, administration of mouse EGF for one day led to food 
intake suppression while intravenous infusion of EGF has been shown to suppress 
nighttime food intake in rats (102, 103).   
Obesity Treatment 
 Given the increase in overweight and obesity, treatment is a necessity and even a 
modest weight loss between 5% and 10% is associated with improvements in such risk 
factors as hypertension, hyperglycemia, and hypercholesterolemia levels, and this weight 
loss has been shown to increase survival (104).  Conventional treatment of obesity 
includes weight loss through reduced caloric intake and increasing physical activity, 
however less than 10% of those who lose weight maintain weight loss (38, 48).  It has 
been reported that an overall better clinical profile is noted with less weight, such as with 
weight loss in moderate and morbid obesity or in individuals of normal body mass index.  
In overweight or obese people, weight loss shows decreased serum levels of many pro-
inflammatory cytokines such as IL6 and TNFA (21, 22, 28, 105, 106).  It has also been 
shown in humans studies that even a modest weight loss brings serum adipokine levels 
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towards a better overall profile such as decreases in serum leptin, resistin, triglycerides, 
and cholesterol levels, improvements in insulin sensitivity, and an increase in serum 
adiponectin (21, 22, 107). 
Another way to treat this disease is to look at signaling within the body related to 
energy homeostasis.  The use of drugs that block lipid absorption or increase satiety 
signals can be used to treat obesity.  Such drugs include orlistat, a lipase inhibitor; 
dexfenfluramine, a serotonin reuptake inhibitor; and sibutramine, which suppresses 
appetite by also inhibiting serotonin and norepinephrine reuptake (104, 108-110).  These 
drugs can be useful as anti-obesity agents however their side effects may limit usage.  
Such side effects include cardiovascular complications with dexfenfluramine and 
sibutramine and gastrointestinal side effects by orlistat (104, 109). Other avenues for 
treatment include manipulation of neuropeptides that affect food intake.  For example, 
since NPY is a stimulator of feeding, antagonizing this protein may aid in decreasing 
obesity (110).     
New therapies are also being assessed which include pharmacological inhibition 
of PAI-1 which is synthesized by adipocytes and is increased in obesity (111, 112); 
inhibition of 11β-hydroxysteriod dehydrogenase type 1 which lowers blood glucose and 
insulin in DIO models (113); and telmisartan inhibition of angiotensin II, which is 
increased in DIO models (114).  These therapies show potential for anti-obesity treatment 
due to decreases or maintenance of body weight, decreases in percentage of body fat, 
decreases in cholesterol and triglyceride concentrations, or decreases in perirenal or 
epididymal fat weight in DIO mice (111, 113, 114).  An alternative anti-obesity treatment 
may be to target EGFR.   
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EGFR is essential for the regulation of normal cell growth and differentiation.  
However, aberrant EGFR activation can also result in the initiation of intracellular 
signaling pathways that promote malignant behavior, including angiogenesis, invasion, 
metastasis, and inhibition of apoptosis (115-117).  EGFR overexpression has been 
reported in many cancers including breast, head and neck, and colon with EGFR 
expression correlating with poor clinical outcome (116).  Due to these factors, 
monoclonal antibodies and TKIs have been directed against this receptor. TKIs interact 
with the intracellular tyrosine kinase domain and inhibit the ligand-induced receptor 
phosphorylation of EGFR by binding to the receptor’s kinase pocket to inhibit signaling 
cascades (115, 117, 118).  AG1478 is a TKI that is highly selective for EGFR with a 
nanomolar range necessary to inhibit 50% of EGFR signaling, while a micromolar range 
is needed for other ERBB receptors (2, 5, 119).  Others have shown that inhibition of 
EGF causes an adipocyte-specific weight decrease with no effect on other organ weights 
(68, 69, 120).  Also, when male Swiss mice were fed a HFD for eight weeks and then 
administered the EGFR TKI PD153035 for two weeks, body weight and fat pad weight 
decreases were noted (121).  Decreased EGFR signaling may decrease low density 
lipoprotein levels (LDLs), which deliver cholesterol to vascular smooth muscle cells 
subsequently leading to atherosclerosis through cell proliferation involving EGFR 
signaling.  Therefore, a decrease in EGFR signaling could lead to a decrease in 
cholesterol levels by inhibiting LDLs and reducing lesion formation (122, 123). Given 
TKI’s specificity to EGFR and adipose specific weight loss, an alternative obesity 
treatment may be to target EGFR. 
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Conclusions 
Obesity results from taking in more calories than required for energy homeostasis 
and can lead to prolonged exposure to lipophilic toxicants.  A balance of food intake and 
energy expenditure, through a highly integrated multi-organ system, determines body 
weight regulation.  Signals relaying energy storage and satiety from the periphery are sent 
to the CNS where they, along with other neuronal signals, are used to maintain this 
balance.  As a result of the worldwide rise in obesity and obesity-related complications 
such as diabetes, stroke, and cardiovascular disease, understanding the mechanisms 
associated with this disease and determining treatment options are necessary.  The EGFR 
is involved in adipogenesis and therefore may contribute to the regulation of energy 
homeostasis.  To assess the role of EGFR in body weight regulation, we first investigated 
the effects of EGFR inhibition pharmacologically with a small molecule inhibitor against 
the EGFR tyrosine kinase (AG1478) or genetically with the Egfrwa2 hypomorphic allele 
in DIO mouse models.  We found that EGFR inhibition slows adipose mass deposition 
due to a decrease in food intake.  Therefore, we deleted Egfr specifically in peripheral 
tissues (intestines and adipocytes) and in the CNS using the Egfrtm1Dwt conditional allele 
and the Villin-Cre, aP2-Cre, and GFAP-Cre, transgenic lines, respectively, to show the 
importance of EGFR activity in regulating adipose deposition in energy homeostasis.  
These studies will aid in our understanding of EGFR signaling within the body with 
respect to obesity and appetite and metabolism regulation. 
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Model Mutation Phenotype 
Egfr-/- Null Dependent on genetic 
background; Organ and 
embryonic abnormalities; Die 
at different stages of 
embryogenesis or postnatally 
(81, 82) 
Egfrwa2 Hypomorph; Glycine to 
valine substitution in 
tyrosine kinase domain 
Homozygous mice - mild 
wavy coat; curly whiskers; 
endocrine and reproductive 
disorders (1) 
Tgfawa1 Spontaneous mutation in 
Tgfa locus 
Homozygous mice – Wavy 
coat; curly whiskers; smaller 
size than controls (83, 84) 
EgfrDsk5 Hypermoph; Missense 
mutation (T to A 
transversion) and 
Leu863Gln substitution  
in tyrosine kinase 
domain 
Abnormal skin pigmentation in 
footpads and first digit; wavy 
coat; thick epidermis; 
increased nail length (85) 
EgfrWa5 Dominant negative; 
Missense mutation (D to 
G change) in tyrosine 
kinase domain 
Peri and prenatal lethality; 
Wavy coat; curly whiskers; 
corneal scarring (74, 86) 
 
Table 1.  Summary of EGFR mutant models and phenotypes. 
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Figure 1.  The epidermal growth factor receptor family, its ligands, and signaling 
pathways. 
(9)
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Figure 2.  Adipogenesis  
(58) 
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Figure 3.  EGFR signaling is necessary at specific stages in adipogenesis. 
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Figure 4.  Adiposity negative feedback loop. 
(32) 
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EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITION RESULTS IN 
DECREASED FAT MASS IN MICE ON A HIGH-FAT DIET DUE TO 
DECREASED FOOD INTAKE 
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Abstract 
Due to worldwide increases in both the prevalence and incidence of obesity, 
understanding the mechanisms behind adipose tissue development and energy 
homeostasis is important.  Accumulating evidence suggests that signaling through the 
epidermal growth factor receptor (EGFR) is required for normal adipocyte development; 
therefore understanding how this signaling contributes to excess body fat mass is 
necessary to unravel the mechanisms associated with obesity.  Our lab has previously 
shown that chronic EGFR inhibition decreases adipose mass deposition in a diet-induced 
obesity model.  In this study, we used both pharmacological and genetic mouse models
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with suppressed EGFR signaling to further delineate the role of EGFR in diet-induced 
obesity. Wild-type C57BL/6J mice were chronically exposed to a high-fat western diet 
with or without a small molecule inhibitor to the EGFR tyrosine kinase, AG1478.  In a 
separate experiment, mice homozygous for the Egfrwa2 mutation, a constitutionally 
impaired EGFR tyrosine kinase, and their control littermates were also challenged with 
this WD.  Monthly MRI and metabolism endpoints and weekly body weight and food and 
water intake measurements were collected.  Upon sacrifice, heart, liver, and fat depots 
were dissected, weighed, and stored.  Brains were also collected for hypothalamic 
extraction.  In both models, there was significantly less fat mass when EGFR was 
inhibited.  Moreover, decreased food intake, feeding efficiency, and smaller adipocyte 
size, as well as improvements in overall clinical profile were observed in mice fed 
AG1478.  These results imply that EGFR signaling may be important in regulating 
energy homeostasis. 
Introduction 
Obesity is just one of the factors associated with metabolic syndrome, which 
includes such symptoms as hypertension, insulin resistance, and hyperlipidemia.  
Metabolic syndrome is also known to be associated with increased inflammatory 
responses such as cytokine and free fatty acid release (26, 27, 124, 125).  Being 
overweight or obese increases the risk of many diseases and health conditions, including 
type 2 diabetes, atherosclerosis, cancer, and stroke.  Also, childhood obesity is associated 
with a higher chance of premature death and disability in adulthood (16, 17).  
Mechanistically, obesity is the result of increased fat mass due to an increase in 
preadipocyte proliferation and adipocyte differentiation.  Recent studies implicating a key 
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role of EGFR in adipogenesis suggest activation of this signaling pathway may contribute 
to obesity.   
The EGFR family is expressed in a wide range of tissues and cell types that 
regulate proliferation, differentiation, motility, and apoptosis (1-4). This family consists 
of four members: ERBB1 (EGFR), ERBB2, ERBB3, and ERBB4 and upon binding of 
ligands to the extracellular domain of these receptors, homo or heterodimers form to 
initiate autophosphorylation of tyrosine residues.  Signaling cascades, such as the 
mitogen-activated protein kinase (MAPK) family of extracellular regulated kinases 
(ERK)-1 and -2, are then initiated which are involved in adipocyte proliferation and 
differentiation (9, 72).  Lipogenic and lipolytic effects are noted for a ligand to EGFR and 
thus studying EGFR signaling cascades may be an important step in understanding the 
underlying mechanisms of adipose deposition and obesity (68-70, 73). 
We have previously shown that female wild-type C57BL/6J mice chronically 
exposed to small molecule EGFR inhibitors exhibit decreased weight gain over the 
course of exposure compared to controls (120). Although we have shown this decrease in 
weight due to fat mass with EGFR inhibition, the mechanisms have not been studied.  
Therefore, we sought to determine the mechanisms behind this phenotype by 
characterizing the metabolic and developmental consequences of EGFR inhibition in 
male wild-type B6 mice.  We found a decrease in food intake and feeding efficiency and 
smaller adipocytes resulting in fat mass reduction.  
Materials and Methods 
Animals and treatment. Mice were bred in house or obtained from The Jackson 
Laboratory (Bar Harbor, ME).  Aged-matched wild-type C57BL/6J (B6) male mice and 
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male mice congenic for the Egfrwa2 allele on B6 and 129S1/SvImJ (129/S1) backgrounds 
were used.  Mice were placed on a high-fat western-style diet (WD, Research Diets, 
D12079B, New Brunswick, NJ, 40% calories from fat) or WD with an inhibitor to the 
epidermal growth factor receptor (EGFR), AG1478 (WD/INH, LC Labs, Billerica, MA, 
0.144g/kg (120)) starting at eight weeks of age for three months.  The WD is nutritionally 
matched with the STD AIN-93G diet (Research Diets, D10012G) except for increased fat 
and reduced fiber, calcium, and vitamin D, more consistent with the diets consumed by 
people in North America.  In the M16 polygenic obesity mouse model, mice were fed a 
control low-fat diet (Research Diets, D12450B, 10% calories from fat) with or without 
AG1478 starting at three weeks of age for two months.  Mice had free access to food and 
water throughout each study.  Body weight and food and water intake measurements 
were collected at the start of the study and every week thereafter.  All mice were 
sacrificed according to an approved University of North Carolina (UNC) Institutional 
Animal Care and Use Committee’s protocol.  Inguinal, epididymal, perirenal, and 
interscapular fat pads, heart, liver, and skeletal muscle were collected and stored at  
-80°C.  Brains were also collected and stored in cold RNAlater for hypothalamic 
extraction. 
Histology.  At necropsy, inguinal, epididymal, perirenal, and interscapular fat 
pads were dissected from control and treated B6 mice, rinsed in PBS, and weighed.  The 
fat pads were formalin-fixed and embedded in paraffin. Sections (7-10 µm) were 
prepared at 100 µm intervals and stained with hematoxylin and eosin (H&E) for 
examination of gross appearance and adipocyte size and number.  Cell counts and area 
 33 
measurements were obtained using ImageJ software from at least 200 cells per fat pad 
(NIH, version 1.41).   
 Indirect Calorimetry.  24-hour caloric expenditure and respiratory exchange rate 
(RER) were measured by indirect calorimetry from B6 mice fed either the WD or 
WD/INH once a month starting at eight weeks of age (126). Briefly, mice were housed 
individually with free access to food and water.  Indirect calorimetry was performed 
using the LabMaster System (TSE Systems, Hamburg, Germany).  Oxygen (O2) 
consumption and carbon dioxide (CO2) production (ml/kg · h) measures were used to 
calculate the RER (Volume CO2 / Volume O2). 
 Activity.  B6 mice fed either the WD or WD/INH were given access to a running 
wheel for one week after the calorimetry measurements.  Mice were housed individually 
in a cage with a solid-surface running wheel attached (145-mm diameter, Ware 
Manufacturing, Phoenix, AZ). Total daily distance (m) and total daily exercise time (sec) 
were recorded every 24 h for each mouse, with average daily running speed (m/sec) 
being subsequently calculated by dividing distance by duration. 
MRI.  Body composition was collected by magnetic resonance imaging (MRI) 
(EchoMRI, Houston, TX) from B6 mice fed either the WD or WD/INH once a month 
starting at eight weeks of age.  
Blood Biochemical Analyses.  Blood samples were collected at the beginning of 
the study and monthly thereafter by tail clip or terminal cardiac puncture.  Serum 
cholesterol and triglycerides were analyzed monthly at the UNC Clinical Chemistry Core. 
Blood glucose levels were measured using a Freestyle Glucose Monitoring System 
(Abbott Laboratories, Abbott Park, IL).  Adipokine measurements including leptin, 
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adiponectin, insulin, interleukin-6 (IL6), tumor necrosis factor-α (TNFA), plasminogen 
activator inhibitor-1 (PAI1), and resistin were analyzed using a mouse serum adipokine 
kit (Linco Research, MADPK-71K, St. Charles, MI) and a BioRad Luminex Instrument 
(Austin, TX). 
Glucose Tolerance Test.  Mice were fasted overnight prior to administration of 
the GTT. d-glucose (Sigma, St. Louis, MO) was dissolved in phosphate buffered saline 
and administered to mice via i.p. injection (2 g/kg). Samples of whole-blood (2–3 µl 
each) were collected from a tail clip bleed immediately before and 15, 30, 60, 90, and 120 
minutes after glucose injection. Blood glucose levels were measured using a Freestyle 
Glucose Monitoring System (Abbott Laboratories, Abbott Park, IL).   
Homeostatic model assessment of insulin resistance. HOMA-IR calculations were 
performed using the HOMA Calculator 2.2.2 (University of Oxford, United Kingdom). 
Acid Steatocrit.  In short, 0.05 g of powdered fecal specimen was mixed in 200 
µL of 1 N perchloric acid. One drop of 0.5% oil red O was added and mixed. Specimens 
were placed in nonheparinized capillary tubes and spun. Steatocrit was calculated as 100 
× length of fatty layer/(length of solid layer + length of fatty layer). 
 Brain processing. Whole brains were collected in cold RNAlater and processed 
within 4 hours.  500 µm whole brain sections from WD and WD/INH fed mice were 
obtained using a vibratome (Leica Instruments, Bannockburn, IL) and collected in 
RNAlater.   The hypothalamus was then microdissected using microforceps and tissue 
isolated by mechanical removal was placed in TRIzol (Invitrogen, Carlsbad, CA) for later 
RNA extraction. 
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Gene expression. Total RNA was extracted from fat pads and brains of B6 mice 
fed WD or WD/INH using TRIzol (Invitrogen).  400 ng of total RNA was reverse 
transcribed using the AffinityScriptTM QPCR cDNA synthesis kit (Stratagene, La Jolla, 
CA). The expression of pre-adipocyte factor (Pref1), CAAT/enhancer binding proteins-
α and β,  (Cebpa; Cebpb), adrenergic receptor β3 (Arb3), fatty acid-binding protein 
(aP2), uncoupling protein-1 (Ucp1), interleukin-6 (Il6), tumor necrosis factor-α (Tnfa), 
leptin (lep), Egfr, pro-opiomelanocortin (Pomc), and neuropeptide Y (Npy) were 
determined by real-time quantitative PCR (qPCR) using the Brilliant® II QPCR Master 
Mix (Stratagene) and Assays-on Demand primers and probes (Applied Biosystems, 
Foster City, CA). Results are represented as mean fold changes relative to controls.  
Reactions were run on a Stratagene MX3000P machine and threshold cycles (CT) were 
determined by an in-program algorithm assigning a fluorescence baseline based on 
readings prior to exponential amplification. Fold change in expression was calculated 
using the 2−ΔΔCt method (127), with ribosomal protein 36B4 and 18s rRNA as the 
endogenous controls for adipose tissue and hypothalamus, respectively. 
Statistics.  Results are expressed as mean ± SEM.  Unpaired t-tests were used to 
determine statistical significance of these measurements between treated and control 
groups using Prism 4.0 (GraphPad).  Repeated measures ANOVAs were used to 
determine statistical significance between energy expenditure and food intake and for 
GTT (SPSS, Chicago, Illinois) and between control and treated groups with regards to 
adipokine measurements (SAS, Cary, North Carolina).  Statistical significant was 
considered at p < 0.05. 
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Results 
Inhibition of EGFR results in reduced fat mass deposition 
Mice homozygous for the waved-2 (Egfrwa2) hypomorphic allele, which reduces 
EGFR activity as much as 90% (1, 128), have significantly lower body weights compared 
to Egfrwa2/+ littermates with normal EGFR activity (Figure 5A).  The reduced body weight 
observed with Egfrwa2/wa2 mice is a consequence of  a reduction in total fat mass with lean 
mass weights indistinguishable between Egfrwa2/wa2 and their control littermates.  This 
effect of reduced EGFR activity is independent of sex or genetic background as both 
males and females from B6- Egfrwa2/wa2 or 129/S1- Egfrwa2/wa2 congenic lines display this 
reduced fat mass compared to their respective control littermates.  Furthermore, this 
effect is independent of diet as mice on a standard chow also have smaller fat masses, 
albeit not as dramatic as mice on a WD (data not shown).  Although only inguinal and 
interscapular fat pads reached significance, all fat depots trended smaller in Egfrwa2/wa2 
mice compared to their control littermates (Figure 5B). 
To determine if pharmacological inhibition of EGFR in adult animals could 
achieve a similar effect as genetic reduction of EGFR that occurs throughout 
development, wild-type male B6 mice were fed a WD with or without the selective 
EGFR inhibitor AG1478 (WD/INH).  Chronic pharmacological inhibition of EGFR 
resulted in a lower body weight due to reduced fat mass, which was observed in all fat 
depots (Figure 5C and Figure 5D, respectively).  Other organ weights were unchanged, 
demonstrating specificity for adipose deposition.  Steatocrit was also measured in the 
feces of these animals and no differences were noted between groups (data not shown).  
A similar decrease in fat mass deposition with AG1478 administration was also observed 
 37 
in the M16 polygenic model of obesity, suggesting the effect of reduced EGFR activity 
on fat deposition is not specific to a diet-induced model (data not shown).   
Reduced fat mass is due to decreased food intake and feeding efficiency 
In order to identify the physiological mechanism responsible for this fat mass 
phenotype observed with decreased EGFR signaling, wild-type male B6 mice on the WD 
or WD/INH were placed in individual calorimeter cages to measure RER and energy 
expenditure.  AG1478 administration resulted in a significant reduction in food intake as 
compared to WD alone (Figure 6A) with no difference in water intake between groups 
(data not shown).  Mice on the WD/INH also showed a lower feeding efficiency as 
compared to mice on the WD alone throughout the study (Figure 6B).  A lower energy 
expenditure was observed throughout the study in mice on the WD/INH compared to WD 
alone.  However, when normalized to food intake, the differences were not significant 
(Figure 6C).  There were also no significant differences in RER (Figure 6D) or in 
voluntary wheel running (data not shown) between groups. 
In addition to measuring energy expenditure indirectly with calorimetry, energy 
usage by thermogenesis was also measured by determining transcript levels of Ucp1 in 
both epididymal (white) and interscapular (brown) adipose tissue.  UCP1 is found in the 
mitochondria of brown adipose tissue and is used to generate heat from stored metabolic 
energy in non-shivering thermogenesis (129).  In both white and brown fat, Ucp1 
transcript levels in animals fed WD/INH were not different from mice fed only the WD 
(Figure 7).   
To determine if EGFR or neuropeptides involved in feeding and energy were 
altered in the hypothalamus of mice fed the WD/INH, whole brains were sectioned and 
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the hypothalamus mechanically removed.  qPCR was used to assess transcript levels of 
Egfr, anorexogenic neuropeptide Pomc, and orexogenic neuropeptide Npy.  No 
differences were observed between groups (Figure 8). 
Inhibition of EGFR results in smaller adipocytes 
To determine if reduced EGFR signaling impacted adipocyte histology, fat pads 
were sectioned and the number of adipocytes counted and normalized to the fat pad 
weights.  Significantly smaller cell area and more adipocytes per fat pad weight were 
observed in mice administered WD/INH compared to WD alone (Table 2 and Figure 9).  
To establish possible causes for the difference in adipocyte size and number, qPCR was 
used to assess transcript levels of adipocyte stage-specific factors in epididymal tissue.  
Preadipocytes were assessed with Pref1 while mature adipocytes were assessed with 
Cebpa, Cebpb, Arb3, and aP2 in epididymal fat pads of these mice.  EGFR inhibition 
caused a significant decrease in Cebpb mRNA levels in mice fed a WD/INH (Figure 10), 
however other adipocyte-specific markers were not different between groups. 
EGFR inhibition leads to improved clinical parameters 
To examine the broader clinical consequences of EGFR inhibition, cholesterol, 
triglyceride, glucose, insulin, and adipokine levels were analyzed in the blood and serum, 
and expression levels of lep and pro-inflammatory cytokines Il6 and Tnfa in the 
epididymal fat pads.   Compared to the mice fed WD alone, mice fed WD/INH showed a 
significantly improved clinical profile for cholesterol and glucose as well as decreased 
lep and Il6 mRNA levels in the fat pads, consistent with lower fat mass in these animals 
(Table 3; Figure 11).  To test whether EGFR inhibition is associated with improved 
insulin resistance in a DIO mouse model, we evaluated insulin sensitivity through 
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measuring homeostasis model assessment of insulin resistance (HOMA-IR) and a glucose 
tolerance test (GTT).  Insulin levels were higher in these animals, however intraperitoneal 
GTT and HOMA-IR levels were not different between groups (Figure 12 and Figure 13, 
respectively).  Consistent with these results, lower cholesterol levels were observed in 
Egfrwa2/wa2 mice compared to control littermates on WD (data not shown).  Although 
values of other clinical parameters measured were not significant at 20 weeks (PAI-
1/SERPINE1, resistin, and adiponectin; data not shown), there was a trend to an overall 
improved clinical profile for all parameters with EGFR inhibition. 
Discussion 
Results reported here demonstrate that pharmacological or genetic inhibition of 
EGFR leads to a reduced fat mass deposition due to decreased food intake and feeding 
efficiency.  Others have shown that inhibition of an EGFR ligand, EGF, causes an 
adipocyte-specific weight decrease with no effect on other organ weights (68, 69, 120), 
similar to what was observed here.  The decreased fat mass observed in this study due to 
pharmacological inhibition is not due to the taste or toxicity of AG1478.  We can 
conclude that this decreased fat mass was not due to the taste of the food because we 
noted this same weight phenotype using the Egfrwa2 fed only the WD.  Also, when male 
Swiss mice were fed a WD for eight weeks and then administered an EGFR TKI, 
PD153035 for two weeks afterwards, similar body weight and fat pad weight decreases 
were noted (68, 69, 120, 121).  As for the toxicity of AG1478, our lab has detected no 
signs of lethargy, dehydration, or ataxia or differences in heart, liver, or kidney weights in 
wild-type male and female mice fed a control diet with AG1478 for 90 days.  Also, this 
pharmacological treatment did delay weight gain in these animals, although treatment and 
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control groups gained weight over the course of the experiment (120).   
Consistent with this decrease in food intake, EGFR inhibition resulted in less 
efficient conversion of food intake to body weight gain.  However, due to the decrease in 
feeding efficiency in these animals, a decrease in food intake alone is insufficient to 
produce this reduced fat mass.  Energy homeostasis is regulated through a balance 
between food intake and energy expenditure.  Energy expenditure can be measured 
indirectly as oxygen consumption and carbon dioxide output (RER) and directly as 
voluntary wheel running, home cage activity, such as climbing, rearing, foraging and 
grooming, and heat production or thermogenesis (130).   There were no differences in 
energy expenditure, RER, or voluntary wheel running between groups.  We have not 
measured home cage activity to see if an increase could be a reason why these mice fed 
WD/INH are leaner than their WD only fed littermates.  Wheel running may or may not 
be a direct reflection of home cage activity in mice fed a HFD since some studies show 
increased home cage activity with increased wheel running while others show no change 
in home cage activity but decreases in wheel running (130-132).  Therefore this 
measurement should be determined to see if differences in home cage activity are aiding 
in this weight loss.  In terms of thermogenesis, UCP1 is found in the mitochondria of 
brown adipose tissue and is used to generate heat from stored metabolic energy by non-
shivering thermogenesis in hibernating mammals and in human infants (95, 129).  It has 
been shown in mice with increased expression of Ucp1 in adipose depots that a lean 
phenotype occurs even when fed a high-fat diet (95).   However, although mice fed 
WD/INH in this study were leaner than their control littermates, their levels of Ucp1 in 
epididymal and interscapular brown fat were not different.  Perirenal, inguinal, and other 
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subcutaneous white adipose depots possess more capacity for brown adipocytes than 
visceral depots and therefore we should analyze the other fat depots collected for brown 
adipocytes and Ucp1 expression (133, 134).  This data now however suggests that this 
body weight and adipose phenotype is due to the decrease in food intake, not to the 
recruitment of brown adipocytes and increased thermogenesis.   
Neuronal signaling within the arcuate nucleus (ARC) of the hypothalamus 
dictates food intake and energy expenditure. We first wanted to determine if EGFR 
expression was affected within the hypothalamus in WD/INH fed mice.  EGFR is 
expressed within the hypothalamus however it was not altered by treatment.  We next 
wanted to determine if alterations in neuropeptides in the ARC associated with feeding 
were different between groups.  Two sets of neurons are found in the ARC; one 
synthesizes orexigenic neuropeptide NPY, which stimulates food intake and decreases 
energy expenditure, and the other synthesizes anorexigenic neuropeptide POMC, which 
reduces food intake and increase energy expenditure (32, 92).  Insulin and leptin reduce 
the expression of  orexigenic neuropeptides and induce expression of anorexigenic 
neuropeptides (31, 93).  No differences in expression levels of either neuropeptide were 
observed in the hypothalamus of these mice.  This suggests that EGFR inhibition with 
AG1478 is not enough to alter mRNA expression of Egfr within the ARC, nor the 
neuropeptides associated with feeding and energy.  However, AG1478 may alter these 
neuropeptides and produce this decrease in food intake without measurable differences in 
mRNA expression.  Other possible mechanisms of this decreased food intake without 
NPY or POMC alteration include AG1478 altering other satiety or appetite 
 42 
neurotransmitters in the brain such as serotonin, dopamine, or melanocyte-stimulating 
hormone (135). 
Since a decrease in fat mass could be due to a reduction in adipocyte cell size 
and/or a decrease in cell number, we histologically analyzed fat pads from mice fed the 
WD or WD/INH.  Adipocyte cell size is smaller and cell number per fat pad mass larger 
in the fat pads of mice fed WD/INH.  To determine causes for these differences between 
groups, we analyzed adipocyte-stage specific genes found in preadipocytes, Pref1, and in 
mature adipocytes, Cebpa, Cebpb, Arb3, and aP2.  We observed a significant decrease in 
Cebpb mRNA levels however, expression of other adipocyte genes were not different 
between groups.  Cebpb is one of the first transcription factors induced after the induction 
of differentiation and it promotes the transcription of a number of other adipogenic genes 
such as Cebpa, Arb3, and aP2 (49, 58, 59).  Although Cebpb is essential for the 
expression of Cebpa and other mature adipocyte markers in vitro for adipocyte 
differentiation, in vivo it has been shown that these factors can be induced without Cebpb 
expression (49).  This suggests that EGFR inhibition does not inhibit differentiation of 
preadipocytes, rather it may cause an arrested differentiation of these cells, given the 
smaller droplets noted in the fat pads of these animals.  This has been noted in Cebpb-/- 
and Cebpb/ Cebpd-/- mice whose epididymal fat pads were significantly smaller than their 
control littermates, although adipocyte-specific markers aP2 and Cebpa were not 
different between groups (49).  
Obesity is thought to be a state of low-grade systemic inflammation with levels of 
adipokines such as TNFA and IL6 elevated in serum and adipose tissue.  It is a complex 
metabolic disorder associated with hyperglycemia, insulin resistance, hypertension, and 
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atherosclerosis.  Disruption in the production and circulation of adipokines such as leptin, 
adiponectin, resistin, PAI1, and insulin, occurs when energy balance is skewed, as in 
obesity, and when obesity is reduced these adipokines can be brought into balance again 
(22, 23, 28, 29, 68).  Diets high in fat are also known to cause insulin resistance and signs 
of inflammation which disrupts adipokine levels.  It has been reported that an overall 
better clinical profile such as decreases in serum leptin, resistin, triglycerides, cholesterol, 
pro-inflammatory cytokines, improvements in insulin sensitivity, and an increase in 
serum adiponectin is noted with less weight, such as with weight loss in moderate and 
morbid obesity or in individuals of normal body mass index (21, 22, 28, 105, 106).  Our 
results show a significant delay in the amount of weight gained in animals fed the 
WD/INH and this weight retardation lead to a significant decrease in serum cholesterol 
levels.  Also observed were significant decreases in mRNA expression levels of lep and 
Il6 between groups, consistent with less fat mass noted in these animals.  This decrease in 
cholesterol levels could be associated with low density lipoprotein levels (LDLs) and 
decreased EGFR signaling.  LDLs deliver cholesterol to vascular smooth muscle cells 
subsequently leading to atherosclerosis through cell proliferation involving EGFR.  
Therefore, a decrease in EGFR signaling could lead to a decrease in cholesterol levels as 
noted in this study by inhibiting LDL levels and reducing lesion formation (122, 123). 
Changes in fat mass can also be associated with changes in glucose and insulin 
homeostasis.  With our experiment, glucose levels were significantly lower in mice fed 
the WD/INH, however in performing the GTT, these animals did not clear glucose 
differently.  However, since insulin levels were higher in mice fed the WD/INH, these 
glucose levels may be just high enough to alter this homeostasis despite the lower fat 
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mass and glucose levels in these animals, although increased insulin resistance is not 
noted (136).  Triglycerides, glucose, and serum and expression levels of other adipokines 
were not significantly altered however these levels were trending towards a better profile.  
Perhaps if these mice were fed the WD/INH for a longer period of time, this better 
clinical profile would be noted.  Therefore, besides potential cholesterol modulation, 
these changes are most likely due to less fat mass observed with EGFR inhibition, rather 
than EGFR directly mediating these changes in clinical parameters. 
In conclusion, we have shown that inhibition of EGFR with a small molecule, 
AG1478, in wild-type B6 mice fed a WD, causes a decrease in body weight due to a 
decrease in food intake and feeding efficiency.  Also observed in mice fed WD/INH is a 
decrease in adipocyte cell size within the fat pads and decreases in some clinical 
parameters suggesting a better overall clinical profile.  Future experiments include 
evaluating the role of EGFR in this food intake phenotype by addressing the role of 
EGFR signaling in energy homeostatic signaling. 
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 Average cell counts/fat pad 
weight 
Average cell area (µm2) 
Fat pad WD WD/INH 
[INH/
WD] 
(%) 
WD WD/INH 
[INH/
WD] 
(%) 
 
Fat pad wt 
[INH/WD] 
(%) 
Epididymal 79 ± 10 144 ± 16* 181 3,364 ± 273 2,995 ± 59 89 75** 
Inguinal 271 ± 41 520 ± 71* 192 2,529 ± 179 1,715 ± 179* 68 74* 
Perirenal 290 ± 28 604 ± 95* 208 3,087 ± 397 2,869 ± 185 93 68** 
 
Table 2. Effects of EGFR inhibition on adipocyte number and size.    
B6 mice fed a WD or WD /INH at 20 weeks of age (N=5-8 animals per fat pad).  Results 
are mean ± SEM.  Statistical significance: * P < 0.05 vs. WD. 
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Table 3. Effects of pharmacological EGFR inhibition on clinical serum parameters.   
Measurements at 20 weeks of age.  N=8 per group.  Results are mean ± SEM.  Statistical 
significance: * P < 0.05, ** P < 0.01, and *** P < 0.0001 vs. WD. 
 
 
Parameter WD WD/INH 
Cholesterol, mg/dL 230 ± 8 184 ± 8** 
Triglycerides, mg/dL 89 ± 17 75 ± 9 
Blood Glucose, mg/dL 161 ± 18 112 ± 3.7*** 
Insulin, ng/mL 1.21 ± 0.12 1.66 ± 0.35* 
Leptin, ng/mL 14.59 ± 2.6 8.57 ± 1.2 
IL6, pg/mL 10.6 ± 4.3 5.69 ± 0.88 
TNFΑ, pg/mL 3.36 ± 0.30 4.52 ± 0.88 
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Figure 5.  Effects of genetic or pharmacological inhibition of EGFR on body weight and 
fat mass.   
Magnetic Resonance Imaging and normalized organ weights of Egfrwa2 littermates (N=7 
(Egfrwa2/+); N=4 (Egfrwa2/wa2)) (A, B) or wild-type C57Bl/6J (C, D) mice fed a WD (N=8) 
or WD/INH (N=8). Results are expressed as the mean ± SEM.  Statistical significance: 
*P < 0.05 vs. wa2/+ or WD; ** P < 0.01 vs. wa2/+ or WD.
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Figure 6.  Effect of pharmacological EGFR inhibition on feeding and metabolic 
parameters.   
Food intake/week (A), feeding efficiency (B), energy expenditure (C) and RER (D) in 
wild-type male B6 mice.  Mice were placed on a WD (N=8) or WD/INH (N=8) for 3 
months.  Energy expenditure is in watts of caloric energy expended per kg of body 
weight.  Results are mean ± SEM.  Statistical significance: ** P < 0.01 vs. WD. 
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Figure 7.  Effect of pharmacological EGFR inhibition on uncoupling protein-1 
expression.   
Epididymal and interscapular fat of B6 mice at 20 weeks of age fed the WD (N=8) or 
WD/INH (N=8).  Results are mean ± standard error. 
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Figure 8. Effect of pharmacological EGFR inhibition on hypothalamic Egfr and 
neuropeptide expression.  
Egfr, Pomc, and Npy mRNA levels in B6 mice at 20 weeks of age fed the WD (N=8) or 
WD/INH (N=8). Results are mean ± standard error. 
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Figure 9. Representative inguinal fat pad histology sections from control and EGFR 
inhibited mice.   
Representative images depicting inguinal fat pads of B6 mice fed a WD (A) or WD/INH 
(B) at 20 weeks of age. 7-10µm sections. 20x magnification. 
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Figure 10.  Effect of pharmacological EGFR inhibition on adipocyte-specific factors in 
epididymal fat.  
B6 mice at 20 weeks of age fed WD (N=8) or WD/INH (N=8). Results are mean ± 
standard error. Statistical significance: * P < 0.05 vs. WD. 
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Figure 11. Effect of pharmacological EGFR inhibition on adipokine transcript expression 
in epididymal fat.  
20 week old B6 mice fed WD (N=8) or WD/INH (N=8). Results are mean ± standard 
error. Statistical significance: * P < 0.05 vs. WD, ** P < 0.01 vs. WD. 
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Figure 12.  Glucose tolerance test measurements from B6 control and EGFR inhibited 
mice. 
20 week old B6 mice fed WD (N=8) or WD/INH (N=8).  Results are mean ± SEM. 
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Figure 13. Effect of pharmacological EGFR inhibition on HOMA-IR measurements. 
20 week old B6 mice fed WD (N=8) or WD/INH (N=8).  Results are mean ± SEM. 
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Abstract 
Obesity results from an imbalance between energy intake and energy expenditure 
and a highly integrated multi-organ system regulates body weight.  Signals relaying 
energy storage and satiety from the periphery are sent to the central nervous system 
(CNS) where they along with other neuronal signals are used to maintain energy 
homeostasis.  The epidermal growth factor receptor (EGFR) is involved in adipogenesis 
and therefore may contribute to energy homeostatic regulation.  Using a diet-induced 
obesity mouse model, we found that inhibition of EGFR either genetically with the 
Egfrwa2 hypomorphic allele or pharmacologically with a small molecule inhibitor against 
the EGFR tyrosine kinase (AG1478) slows adipose mass deposition due to a decrease in 
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food intake.  To determine the role of EGFR in adipose deposition within energy 
homeostatic regulation, we deleted Egfr specifically in peripheral tissues (intestines and 
adipocytes) and in the CNS using the Egfrtm1Dwt conditional allele and the Villin-Cre, 
aP2-Cre, and GFAP-Cre transgenic lines, respectively.  All mice were fed a high-fat 
western diet over three months.  Body weight and MRI measurements were collected 
monthly and upon sacrifice, heart, liver, and fat depots were dissected, weighed, and 
stored.  Brains were also collected for later hypothalamic extraction.  Ablation of EGFR 
within the intestinal epithelium and adipocytes showed no effect on adipose deposition.  
However, deletion specifically within the CNS caused a significant reduction in adipose 
mass with consequent smaller adipocytes in fat pads, hyperphagia, increased energy 
expenditure, and improved clinical profile.  The phenotype is due in part to increases in 
energy expenditure from hyperactivity, thermogenesis, and white adipose tissue lipolysis.  
Introduction 
The balance between food intake and energy expenditure is regulated through a 
highly integrated multi-organ system.  Satiety and adiposity signals from the intestines 
and adipose tissue are sent to the central nervous system (CNS) where they, along with 
other neuronal signals, are used to maintain this balance.  Obesity results from taking in 
more calories than expended and is just one of the factors associated with metabolic 
syndrome, which includes such symptoms as hypertension, insulin resistance, and 
hyperlipidemia.  Metabolic syndrome is also known to be associated with increased 
inflammatory responses such as cytokine and free fatty acid release (26, 27, 124, 125). 
Being overweight or obese increases the risk of many diseases and health conditions, 
including type 2 diabetes, atherosclerosis, cancer, and stroke (16, 17).  Recent studies 
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implicating a key role of the epidermal growth factor receptor (EGFR) in adipogenesis 
suggest signaling through this receptor may contribute to obesity, and therefore in the 
regulation of energy homeostasis. 
The EGFR is the prototypical member of the ERBB family, which are expressed 
in a wide range of tissues and cell types and regulate a number of cellular processes such 
as proliferation, differentiation, motility, apoptosis, and survival (1-4). The ERBB family 
consists of four members: ERBB1 (EGFR), ERBB2, ERBB3, and ERBB4 and upon 
binding of ligands to the extracellular domain, these receptors homo or heterodimerize to 
initiate autophosphorylation of tyrosine residues (3-6). Signaling cascades, such as the 
mitogen-activated protein kinase (MAPK) family of extracellular regulated kinases 
(ERK)-1 and -2, are then initiated, many of which are involved in adipocyte proliferation 
and differentiation (9, 72).  Lipogenic and lipolytic effects have also been reported for 
EGFR ligands (68-70, 73).  Thus studying EGFR signaling is important for understanding 
the underlying mechanisms of adipose deposition and obesity. 
We have shown that EGFR inhibition, either pharmacologically or genetically, 
decreases adipose deposition in mice fed a high-fat western diet (WD), but does not 
affect the mass of other organs.  Also, we have shown that this decrease in fat mass is due 
to a reduction in food intake without changes in energy expenditure.  Therefore, given 
this adipose specificity and feeding phenotype, we examined the molecular mechanisms 
underlying this reduction in adipose mass.  We modeled a typical WD and determined the 
effect on adipose deposition and energy homeostasis when Egfr was specifically deleted 
in adipocytes, intestines, and the CNS using the ap2-Cre, Villin-Cre, and GFAP-Cre 
transgenic mouse lines, respectively. 
 59 
Methods and Materials 
Animals and treatment. aP2-Cre, Villin-Cre, and GFAP-Cre transgenic mice were 
mated with Egfrflox/+or Egfrflox/flox  mice (137, 138).  ap2-Cre (and Villin-Cre and GFAP-
Cre) x Egfrflox/flox male mice with their control littermates (-Cre, -CreEgfrflox/+, Egfrflox/+, 
or Egfrflox/flox) were started on a high-fat western diet (WD, Research Diets, D12079B, 
New Brunswick, NJ, 40% calories from fat) (113) at eight weeks of age for three months. 
The WD is nutritionally matched with the STD AIN-93G diet (Research Diets, 
D10012G) except for increased fat and reduced fiber, calcium, and vitamin D, more 
consistent with the diets consumed by people in North America.  Mice had free access to 
food and water throughout each study.  Body weight and food and water intake 
measurements were collected at the start of the study and every week thereafter.  All mice 
were sacrificed according to an approved University of North Carolina (UNC) 
Institutional Animal Care and Use Committee’s protocol.  Inguinal, epididymal, 
perirenal, and interscapular fat pads, heart, liver, and skeletal muscle were collected and 
stored at -80°C.  Brains were also collected and stored in cold RNAlater for hypothalamic 
extraction. 
Genotyping. Genotyping was performed by PCR to determine presence of Cre 
and floxed alleles.  The Egfrflox allele was amplified from genomic DNA for 35 cycles (30 
s at 94°C, 1 min at 60°C, and 1 min at 72°C). The primers used were lox3s: 5’CTTTGG-
AGAACCTGCAGATC-3’ and lox3as: 5’CTGCTACTGGCT-CAAGTTTC-3’. A 375 bp 
PCR product was detected from the Egfrflox allele and a 320 bp PCR product from the 
wild-type allele. For the EgfrΔ allele showing Egfr excision, genomic DNA was amplified 
for 40 cycles (30 s at 94°C, 20 s at 60°C, and 20 s at 72°C). The primers used were Delta-
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3: 5’-CTCAGCCAGATGATGTTGAC-3’ and Delta-4: 5’-CCTCGTCTGTGGAAGA-
ACTA-3’. A 129 bp PCR fragment was detected from the EgfrΔ allele.  For the Cre 
transgene, DNA was amplified for 38 cycles (30 s at 94°C, 1 min at 56°C, and 1 min at 
72°C) with primers CRE-1: 5’-GTGATGAGGTTCGCAA-GAAC-3’ and CRE-2: 
5’AGCATTGCTGTCACTTGGTC-3’. A 278 bp PCR fragment was generated from the 
Cre transgene.  All PCR products were run on a 3% agarose gel at 150mV for 25 minutes 
and all reactions used Taq DNA polymerase (Qiagen, Germantown, MD) and a 
GeneAmp PCR system 9700 (Applied Biosystems, Foster City, CA). 
 Indirect Calorimetry.  24-hour caloric expenditure, oxygen consumption, and 
respiratory exchange rate (RER) were measured by indirect calorimetry from GFAP-Cre 
Egfrflox/flox mice and their control littermates once a month starting at eight weeks of age 
(126).  Briefly, mice were housed individually with free access to food and water.  
Indirect calorimetry was performed using the LabMaster System (TSE Systems, 
Hamburg, Germany).  Oxygen (O2) consumption and carbon dioxide (CO2) production 
(ml/kg · h) measures were used to calculate the RER (Volume CO2 / Volume O2). 
 Activity.  GFAP-Cre Egfrflox/flox mice and their control littermates were given 
access to a running wheel for one week after the calorimetry measurements.  Mice were 
housed individually in a cage with a solid-surface running wheel attached (145-mm 
diameter, Ware Manufacturing, Phoenix, AZ). Total daily distance (m) and total daily 
exercise time (sec) were recorded every 24 h for each mouse, with average daily running 
speed (m/sec) being subsequently calculated by dividing distance by duration. 
Acid Steatocrit.  In short, 0.05 g of powdered fecal specimen was mixed in 200 
µL of 1 N perchloric acid. One drop of 0.5% oil red O was added and mixed. Specimens 
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were placed in nonheparinized capillary tubes and spun. Steatocrit was calculated as 100 
× length of fatty layer/(length of solid layer + length of fatty layer). 
Blood Biochemical Analyses. Blood samples were collected at the beginning of 
the study and monthly thereafter by tail clip or terminal cardiac puncture.  Serum 
cholesterol and triglycerides were analyzed monthly at the UNC Clinical Chemistry Core. 
Blood glucose levels were measured using a Freestyle Glucose Monitoring System 
(Abbott Laboratories, Abbott Park, IL). Adipokine measurements including leptin, 
insulin, tumor necrosis factor-α (TNFA), plasminogen activator inhibitor-1 (PAI1), and 
resistin were analyzed using a mouse serum adipokine kit (Linco Research, MADPK-
71K, St. Charles, MI) and a BioRad Luminex Instrument (Austin, TX).   
Glucose Tolerance Test. Mice were fasted overnight prior to administration of the 
GTT.  d-glucose (Sigma, St. Louis, MO) was dissolved in phosphate buffered saline and 
administered to mice via i.p. injection (2 g/kg). Samples of whole-blood (2–3 µl each) 
were collected from a tail clip bleed immediately before and 15, 30, 60, 90, and 120 
minutes after glucose injection. Blood glucose levels were measured using a Freestyle 
Glucose Monitoring System (Abbott Laboratories, Abbott Park, IL).  
Homeostatic model assessment of insulin resistance. HOMA-IR calculations were 
performed using the HOMA Calculator 2.2.2 (University of Oxford, United Kingdom). 
 Brain processing.  Whole brains were collected in cold RNAlater and processed 
within 4 hours.  500 µm whole brain sections from control and GFAP-Cre Egfrflox/flox 
mice were obtained using a vibratome (Leica Instruments, Bannockburn, IL) and 
collected in RNAlater.   The hypothalamus was then microdissected using microforceps 
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and tissue isolated by mechanical removal was placed in TRIzol (Invitrogen, Carlsbad, 
CA) for later RNA extraction. 
Gene expression. Total RNA was extracted from fat pads and brains using TRIzol 
(Invitrogen).  400 ng of total RNA was reverse transcribed using the AffinityScriptTM 
QPCR cDNA synthesis kit (Stratagene, La Jolla, CA). The expression of pre-adipocyte 
factor-1 (Pref1), CAAT/enhancer binding proteins-α and β, (Cebpa and Cebpb), 
adrenergic receptor β3 (Arb3), fatty acid-binding protein (aP2), leptin (lep) , uncoupling 
protein-1 (Ucp1) and Ucp3, tumor necrosis factor-α (Tnfa), Egfr, pro-opiomelanocortin 
(Pomc), and neuropeptide Y (Npy) were determined by real-time quantitative PCR 
(qPCR) using the Brilliant® II QPCR Master Mix (Stratagene) and Assays-on Demand 
primers and probes (Applied Biosystems). Results are represented as mean fold changes 
relative to controls.  Reactions were run on a Stratagene MX3000P machine and 
threshold cycles (CT) were determined by an in-program algorithm assigning a 
fluorescence baseline based on readings prior to exponential amplification. Fold change 
in expression was calculated using the 2−ΔΔCt method (127), with ribosomal protein 
36B4, 18s rRNA, and β-actin as the endogenous controls for adipose tissue, 
hypothalamus, and liver, respectively. 
Statistics.  Results are expressed as mean ± SEM.  Unpaired t-tests were used to 
determine statistical significance of these measurements between groups using Prism 4.0 
(GraphPad).  Repeated measures ANOVAs were used to determine statistical 
significance of caloric energy expenditure, wheel running, and GTT between groups 
(SPSS).  Statistical significant was considered at p < 0.05. 
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Results 
Egfr ablation within the CNS results in reduced fat mass deposition 
Previously our lab showed that inhibition of EGFR produces lower body weights 
and fat mass in animals fed a high-fat WD due to a decrease in food intake without 
changing activity or energy expenditure.  To determine the origin of EGFR-mediated fat 
mass deposition, a Cre-loxP strategy was used to specifically ablate Egfr activity in 
selected organs.  Egfrflox/flox mice that contain loxP sites flanking exon 3 of the Egfr gene 
were created in our laboratory and bred to three established transgenic Cre lines (Villin-
Cre, aP2-Cre, and GFAP-Cre) to delete EGFR within intestines, adipocytes, and CNS, 
respectively (137).  The resulting Cre Egfrflox/flox mice did not exhibit overt phenotypes 
when compared to their Egfr wild-type littermates and therefore wild-type, Egfrflox/+, and 
Cre mice were considered as controls (138-140).  Eight week-old male littermates from 
each mating were housed individually and placed on the WD for three months.  Ablation 
of Egfr within the intestinal epithelium with Villin-Cre or within adipocytes with aP2-
Cre had no effect on adipose deposition (Figure 14A and Figure 14B).  However, 
deletion of Egfr activity in the CNS with GFAP-Cre resulted in decreased total and fat 
mass without an effect on lean mass (Figure 14C and Figure 14D).  Brain weights were 
larger in GFAP-Cre Egfrflox/flox mice compared to controls, although all other organs 
weights were unchanged between groups (Figure 14E). Steatocrit was also measured in 
the feces of these animals and no differences were noted between groups (data not 
shown).  Therefore, Egfr signaling within the CNS aids in controlling adipose deposition. 
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Use of the GFAP-Cre transgene leads to reduced Egfr and anorexigenic neuropeptide in 
the hypothalamus 
To determine the physiological mechanisms behind the fat mass phenotype with 
deleted Egfr in the CNS, GFAP-Cre Egfrflox/flox mice and their control littermates were 
placed in individual calorimeter cages three days per month for three months to measure 
RER and caloric energy expenditure, fed the WD as before.  CNS deletion of Egfr with 
GFAP-Cre resulted in significantly increased food and water intake and decreased 
feeding efficiency as compared to control littermates (Figure 15).  We also observed an 
increase in caloric energy expenditure and oxygen consumption in these mice (Figure 
16A and Figure 16B).  However, no differences in activity, measured by voluntary wheel 
running (Figure 16C and Figure 16D), or in RER (data not shown) were observed 
between groups.   
In addition to measuring energy expenditure indirectly with calorimetry, energy 
usage was also measured by determining transcript levels of uncoupling protein-1 (Ucp1) 
in both epididymal (white) and interscapular (brown) adipose tissue.  UCP1 is found in 
the mitochondria of brown adipose tissue and is used to generate heat from stored 
metabolic energy in non-shivering thermogenesis (129).  In both white and brown fat, 
Ucp1 transcript levels were not different between groups, although levels in white fat 
trended higher in GFAP-Cre Egfrflox/flox mice than control littermates (Figure 17A).  
Expression of Ucp3 was also measured in skeletal muscle but no difference was observed 
between groups (Figure 17B). 
To verify that Egfr was deleted in the hypothalamus with GFAP-Cre and to 
identify changes in feeding peptides within this area, whole brains were sectioned and the 
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hypothalamus mechanically removed.  qPCR was used to assess transcript levels of Egfr, 
anorexigenic neuropeptide Pomc, and orexigenic neuropeptide Npy.  Levels of Pomc and 
Egfr were significantly decreased in GFAP-Cre Egfrflox/flox mice compared to their control 
littermates (Figure 18). 
Ablation of EGFR results in smaller adipocytes 
To determine if CNS deletion of EGFR impacted adipocyte histology, fat pads 
were sectioned and the number of adipocytes counted and normalized to the fat pad 
weights.  Significantly smaller cell area and more adipocytes per fat pad weight were 
observed in GFAP-Cre Egfrflox/flox mice compared to control littermates (Table 4 and 
Figure 19).   To establish possible causes for the difference in adipocyte size and number, 
qPCR was used to assess transcript levels of adipocyte stage-specific factors.  
Preadipocytes were assessed with Pref1 while mature adipocytes were assessed with 
Cebpa, Cebpb, Arb3, and aP2 in epididymal fat pads of these mice.  A significant 
increase in Arb3 mRNA levels was observed in GFAP-Cre Egfrflox/flox mice compared to 
controls (Figure 20); no other adipocyte-specific markers were different between groups. 
Egfr deletion in the CNS leads to improved clinical parameters 
To examine the broader clinical consequences of Egfr deletion in the CNS, 
cholesterol, triglyceride, glucose, insulin, and adipokine levels were analyzed in the 
blood and serum, and expression levels of lep and pro-inflammatory cytokine 
Tnfa in epididymal fat pads.  GFAP-Cre Egfrflox/flox mice showed a significantly improved 
clinical profile for cholesterol, triglycerides, leptin, and insulin in the serum as well as 
decreased lep mRNA levels in the fat pads, consistent with lower fat mass in these 
animals.  Although not significant, an increase in serum and mRNA expression levels of 
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TNFA were observed (Table 5).  To test whether Egfr deletion in the CNS is associated 
with improved insulin resistance in a DIO mouse model, we evaluated insulin sensitivity 
through measuring homeostasis model assessment of insulin resistance (HOMA-IR) and 
a glucose tolerance test (GTT).  Intraperitoneal GTT were not different between groups, 
however HOMA-IR was significantly decreased in GFAP-Cre Egfrflox/flox mice (Figure 21 
and Figure 22, respectively). 
Discussion 
The body maintains a balance between energy intake and energy expenditure and 
obesity results from taking in more calories than expended. Obesity is just one of the 
factors associated with metabolic syndrome, which includes such symptoms as 
hypertension, insulin resistance, and hyperlipidemia (26, 27, 124, 125).  Recent studies 
implicating a key role for EGFR in adipogenesis suggest signaling through this receptor 
may contribute to obesity. Using a diet-induced obesity mouse model, our lab previously 
found that genetic and pharmacological inhibition of EGFR caused a retardation in 
weight gain and adipose deposition due to a reduction in food intake.  Others have also 
shown adipocyte-specific weight decreases with EGFR downregulation (68, 69, 120, 
121).   
To determine the role of EGFR in energy homeostasis, we employed the Cre-loxP 
system to delete Egfr specifically in the periphery (intestines and adipocytes) and in the 
CNS.  Although deletion of Egfr within intestines or adipocytes had no effect on fat 
mass, deletion of Egfr in the CNS results in decreased total and fat mass, showing that 
EGFR signaling within the CNS is important for normal adipose deposition.  Brain 
weights normalized to body weight in GFAP-Cre Egfrflox/flox mice were increased 
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compared to control littermates, while other organ weights were not different.  Since 
brains from GFAP-Cre Egfrflox/flox mice do not show any morphological changes relative 
their control littermates (138) the increase in brain weight may be a consequence of the 
low body weight in these animals since no differences are noted on a wet brain weight 
basis. 
Since the balance of energy homeostasis is dependent on both energy intake and 
energy expenditure, we evaluated these two components to determine the physiological 
mechanism of the Egfr mutant phenotype.  We demonstrate an increase in food intake 
and a decrease in feeding efficiency in GFAP-Cre Egfrflox/flox mice compared to their 
control littermates.  Due to the difference in feeding efficiency between groups, perhaps 
energy expenditure is also affected, producing lower body weights.  Energy expenditure 
can be measured indirectly as oxygen consumption and carbon dioxide output (RER and 
caloric energy expenditure) or directly as voluntary wheel running, home cage activity, 
such as climbing, rearing, foraging and grooming, and heat production or thermogenesis. 
Consistent with an increase in food intake, deletion of Egfr with GFAP-Cre resulted in an 
increased conversion of food energy to heat energy and increased oxygen consumption as 
measured by indirect calorimetry, suggesting hyperkinesia in these animals.  However, no 
differences in RER or voluntary wheel running were observed between groups.  The 
control mice did decrease the distance ran over time as they became obese, possibly 
because they found it harder to move around, which could be responsible for their further 
increase in obesity.  We have not measured home cage activity to see if an increase could 
be a reason why GFAP-Cre Egfrflox/flox mice are leaner than their control littermates.  
Wheel running may or may not be a direct reflection of home cage activity in mice fed a 
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HFD since some studies show increased home cage activity with increased wheel running 
while others show no change in home cage activity but decreases in wheel running (130-
132).  Home cage activity should then be measured to assess if it is increased and aiding 
in this decrease in body weight and fat mass.  Therefore this data suggests that deletion of 
Egfr using GFAP-Cre regulates appetite and metabolism in these animals but not their 
activity through wheel running activity.   
Other studies have also shown this increase in food intake and energy expenditure 
with a decrease in body weight and have attributed it in part to an increase in 
thermogenesis (25, 129).  Adaptive thermogenesis is the dissipation of heat energy in 
response to external stimuli and it has been implicated in the regulation of energy balance 
and body temperature.  In rodents, adaptive thermogenesis in response to cold-exposure 
and high-fat feeding activates brown adipose tissue.  UCP1 is found in the mitochondria 
of brown adipose tissue and is used to generate heat from stored metabolic energy by 
non-shivering thermogenesis in hibernating mammals and in human infants.  In mice 
with increased expression of Ucp1 and increased food intake, a lean phenotype occurs 
even when fed a high-fat diet (25, 95, 129).  Ucp1 expression levels in interscapular 
tissue were not different between groups, however levels in epididymal tissue were 
increased although not significantly in GFAP-Cre Egfrflox/flox animals.  Perirenal, inguinal, 
and other subcutaneous white adipose depots possess more capacity for brown adipocytes 
than visceral depots and therefore they should be analyzed for brown adipocytes and 
Ucp1 expression (133, 134).  Recent data has shown that brown and white adipocytes are 
present together in the same depots and may convert to the other type depending on 
energy needs (52, 53).  Therefore, increased Ucp1 expression in the epididymal or other 
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fat pads of these animals suggests more brown adipocytes in the white adipose tissue of 
these animals.  Promotion of brown fat adipogenesis in these depots could therefore 
contribute to increased thermogenesis and the decreased fat mass observed.  Another 
uncoupling protein thought to be associated with energy metabolism is UCP3.  It is 
expressed predominantly in skeletal muscle and similar to UCP1 in brown adipose tissue, 
is upregulated after the consumption of a high-fat diet in rodents and humans(141).  Mice 
overexpressing UCP3 eat considerably more than their wild-type littermates, but do not 
become obese, suggesting that metabolic rate is increased in these animals.  In this study 
no difference in Ucp3 expression was observed between groups, suggesting that Ucp3 
expression in skeletal muscle does not affect energy metabolism with perturbed EGFR in 
the CNS (141-143). 
Neuronal signaling within the arcuate nucleus (ARC) of the hypothalamus 
evaluates energy intake and energy expenditure.  GFAP-labeled astrocytes implicated in 
feeding are found within the ARC.  These astrocytes play an important role in regulating 
food intake by monitoring fat stores and lipid metabolism.  Hypothalamic astrocytes have 
been shown to express EGFR and this is well preserved between rodents and humans (10, 
103, 138, 144).  Egfr expression was significantly reduced within the hypothalamus in 
GFAP-Cre Egfrflox/flox mice.  Thus deletion of Egfr using the GFAP promoter in the ARC 
is possibly responsible for the alteration in feeding and energy expenditure. Two key sets 
of neurons important for conveying appetite and energy are found in the ARC; one 
synthesizes orexigenic NPY, which stimulates food intake and decrease energy 
expenditure, and the other synthesizes anorexigenic neuropeptide POMC, which reduces 
food intake and increases energy expenditure.  Insulin and leptin reduce the expression of 
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orexigenic neuropeptides and induce expression of anorexigenic neuropeptides (31, 32, 
92, 93).  Other studies have shown that diet-induced obesity and weight loss alter 
neuropeptide expression in the ARC to increase or decrease feeding and energy 
expenditure (78, 145).  Expression levels of anorexigenic neuropeptide Pomc in the 
hypothalamus of GFAP-Cre Egfrflox/flox mice was reduced compared to control littermates.  
Since stimulation of POMC neurons decrease food intake, with decreased expression we 
see an increase in food intake in GFAP-Cre Egfrflox/flox mice.  Also consistent with this 
downregulation of Pomc is the significant decrease in insulin and leptin levels.  This 
suggests that this reduction in Egfr expression within the hypothalamus of GFAP-Cre 
Egfrflox/flox mice leads to an increase in food intake by downregulating anorexigenic 
neuropeptide Pomc, further evidenced by the reduction of leptin and insulin.    
Since a decrease in fat mass could also be due to a reduction in adipocyte cell size 
and/or a decrease in cell number, we analyzed fat pads from these animals.  Adipocyte 
cell size is smaller and cell number per fat pad mass larger in the fat pads of the GFAP-
Cre Egfrflox/flox mice compared to control littermates.  To determine causes for these 
differences in the GFAP-Cre Egfrflox/flox fat pads, we analyzed adipocyte-stage specific 
genes found in preadipocytes, Pref1, and in mature adipocytes, Cebpa, Cebpb, Arb3, and 
aP2.  We observed a significant increase in Arb3 mRNA levels, although expression of 
other adipocyte genes were not different between groups.  This increase in Arb3 may not 
be related to the amount of mature adipocytes in the fat pads.  Rather this increased 
expression may be involved in increasing lipolysis in these depots, leading to a decrease 
in fat mass.   
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White adipose tissue stores triglycerides in periods of energy excess and in times 
of energy need, lipolysis of triglycerides occurs.  ARB3 is a member of the large family 
of G protein-coupled receptors (GPCRs) that couple to members of the heterotrimeric G 
proteins to activate adenylyl cyclase and cAMP-dependent protein kinase A (PKA).  PKA 
then phosphorylates hormone sensitive lipase, which then aids in lipase access to lipid 
droplets and triglyceride breakdown by altering proteins on the droplet’s surface.    
Stimulation of the ARBs leads to lipolysis in white adipocytes and non-shivering 
thermogenesis in brown adipocytes and ARB3 activation of the MAPK pathway accounts 
for 15 to 25% of total lipolysis in white adipocytes in rodents (95, 96, 99, 146).  In 
GFAP-Cre Egfrflox/flox mice, a significant decrease in body fat and serum triglycerides is 
observed with increases in energy expenditure and possible thermogenesis in white 
adipose tissue, suggesting increased fatty acid oxidation within the epididymal depots.   
This phenotype is also observed in mice that overexpress a triglyceride hydrolase in 
white adipose tissue or are treated with an orexigenic melanin-concentrating hormone-1 
(MCH1) receptor antagonist (147, 148).  In both of these models, increased lipolysis is 
specific to white adipose tissue without increased circulating levels of fatty acids.  
Therefore, the increased Arb3 expression may cause mobilization of triglycerides from 
white adipose tissue or increased thermogenesis in brown adipocytes leading to a 
reduction of body fat mass.  These fatty acids could either be brought back into the 
adipocyte for oxidation and energy or could be liberated into the serum.  The fatty acids 
liberated from white adipose depots into the serum could have detrimental effects on 
metabolism and cause ectopic lipid storage on other organs however and therefore where 
these fatty acids are going in this model needs to still be determined.  We do not see 
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excess fat in the feces of these animals however we do need assess other locations for 
increased fatty acids such as in the liver and around other organs.  Increased delivery of 
fatty acids into the portal venous system could affect liver metabolism through alterations 
in glucose production, lipoprotein secretion, and insulin clearance (149).  Therefore 
increased adipocyte oxidation with or without increased serum fatty acids may play a 
significant role in the adiposity and energy metabolism phenotypes observed in these 
GFAP-Cre Egfrflox/flox mice (147, 148, 150, 151).    
Obesity is thought to be a state of low-grade systemic inflammation with levels of 
adipokines such as TNFA and IL6 elevated in serum and adipose tissue.  It is a complex 
metabolic disorder associated with hyperglycemia, insulin resistance, hypertension, and 
atherosclerosis (21, 23, 25, 152).  Disruption in the production and circulation of 
adipokines such as leptin, adiponectin, and insulin, occurs when energy balance is 
skewed, as in obesity, and when obesity is reduced these adipokines can be brought into 
balance again.  Diets high in fat are also known to cause insulin resistance and signs of 
inflammation which disrupts adipokine levels (22, 28, 29).   It has been reported that an 
overall better clinical profile such as decreases in serum leptin, triglycerides, and 
cholesterol levels, and improvements in insulin sensitivity is observed with weight loss in 
moderate and morbid obesity or in individuals of normal body mass index (21, 22, 28, 
105, 106).  Our results show a significant delay in the amount of weight gained in GFAP-
Cre Egfrflox/flox animals and this weight retardation lead to a significant decrease in serum 
cholesterol, triglyceride, leptin, and insulin levels. Also observed were significant 
decreases in mRNA expression levels of lep in epididymal fat pads between groups, 
consistent with less fat mass noted in these animals.  In overweight or obese people, 
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decreased serum levels of many pro-inflammatory cytokines are observed with less 
weight.  TNFA levels in the serum and mRNA expression in white adipose tissue were 
increased in the GFAP-Cre Egfrflox/flox animals, however not significantly.  As mentioned 
previously, the phenotypes observed in the GFAP-Cre Egfrflox/flox mice may be due to an 
increase in lipolysis in white adipose tissue.  Adipocytes regulate lipolysis locally by 
releasing TNFA, which inhibits anti-lipolytic pathways, and perhaps this increase in Tnfa 
expression in adipocytes is for this process (146, 153).  Changes in fat mass can also be 
associated with changes in glucose and insulin homeostasis.  In this model, deletion of 
EGFR in the CNS attenuated insulin resistance as shown by improved HOMA-IR values 
and, although not significant, decreased glucose levels and improved glucose tolerance 
(136).  Therefore, this overall better profile is most likely due to less fat mass observed 
with EGFR CNS deletion, rather than EGFR directly mediating these changes in clinical 
parameters.  
In conclusion, EGFR signaling is important in the balance of energy homeostasis 
within these animals by affecting their appetite and metabolism.  The deletion of Egfr 
with GFAP-Cre leads to an increase in food intake by altering hypothalamic neuropeptide 
levels important in feeding, yet a lower body weight is observed.  The lower body weight 
may be due to an environment produced within adipocytes for increased lipolysis by 
upregulating the expression of genes that aid in this process or by increasing the amount 
of brown adipocytes within white adipose tissue.  The decrease in body weight and fat 
mass observed in GFAP-Cre Egfrflox/flox animals also produces mice with a better overall 
clinical profile and increased insulin sensitivity.  Ultimately, the question as to how this 
decrease in Egfr within the hypothalamus alters neuropeptide expression and how these 
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alterations signal to the periphery for decreased body weight and perhaps increased fatty 
acid oxidation remains.  Future directions include determining if lipolysis is occurring 
within white adipose stores and the effect on fatty acid levels.   If fatty acids are taken 
back into the adipocyte for oxidation or use in triglyceride synthesis, then they would not 
be liberated into the circulation to cause detrimental effects on glucose and insulin 
metabolism.  Also, it will be important to evaluate if more brown adipocytes are observed 
in the white fat depots of GFAP-Cre Egfrflox/flox animals.  These measures will aid in our 
understanding of EGFR signaling within the CNS with respect to appetite and 
metabolism regulation. 
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 Average cell counts/fat pad 
weight 
Average cell area (µm2) 
Fat pad Control 
 
Gfap-Cre 
 
[Cre/
ctrl] 
(%) 
Control 
 
Gfap-Cre 
 
[Cre/
ctrl] 
(%) 
 
Fat pad wt 
[Cre/ctrl] 
(%) 
Epididymal 49 ± 6.9 265 ± 48* 543 6,785 ± 133 3,264 ± 107*** 48 36*** 
Inguinal 191 ± 16 933 ± 212** 490 3,591 ± 139 2,248 ± 284* 63 56 
 
Table 4.  Effects of Egfr CNS deletion with GFAP-Cre on adipocyte number and size. 
GFAP-Cre Egfrflox/flox mice and their control littermates were fed a WD for 3 months 
(N=3-8 animals per fat pad).  Results are mean ± SEM.  Statistical significance: * P < 
0.05 , ** P < 0.01 and *** P < 0.0001 vs. control. 
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Parameter Control GFAP-Cre Egfrflox/flox 
Cholesterol, mg/dL 222 ± 17 152 ± 27* 
Triglycerides, mg/dL 135 ± 9.5 89 ± 16* 
Blood Glucose, mg/dL 214 ± 16 163 ± 23 
Leptin, ng/mL 31.1 ± 3.2 10 ± 5.2** 
Leptin, fold change/control 1 ± 0.14 0.29 ± 0.17** 
Insulin, ng/mL 1.46 ± 0.19  0.73 ± 0.25* 
PAI-1, ng/mL 4.37 ± 0.86 4.45 ± 1.1 
Resistin, ng/mL 5.23 ± 0.51 4.39 ± 1.4 
TNFA, pg/mL 9.89 ± 2.5 31.9 ± 11 
TNFA, fold change/control 1 ± 0.2 2.66 ± 1.1 
 
Table 5.  Clinical serum and expression data from control and GFAP-Cre Egfrflox/flox 
mice.   
Measurements are at 20 weeks of age for control (N=10) and GFAP-Cre Egfrflox/flox (N=6) 
mice. Results are mean ± SEM.  Statistical significance: * P < 0.05 and ** P < 0.01 vs. 
control. 
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Figure 14. Effects of conditional deletion of Egfr on body masses and organ weights.   
MRI data of Villin-Cre Egfrflox/flox (A), aP2-Cre Egfrflox/flox (B), and GFAP-Cre Egfrflox/flox 
(C) and their control littermates fed a WD.  Normalized organ weights in GFAP-Cre 
Egfrflox/flox mice (D, E). N=4 Villin-Cre Egfrflox/flox; N=6 Villin-Cre controls; N=10 aP2-
Cre Egfrflox/flox; N=12 aP2-Cre controls; N=6 GFAP-Cre Egfrflox/flox; N=10 GFAP-Cre 
controls. Results are expressed as mean ± SEM. Statistical significance: * P < 0.05, ** P 
< 0.01, and *** P < 0.0001 vs. control.   
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Figure 15. Effects of Egfr CNS deletion with GFAP-Cre on food and water intake and 
feeding efficiency.   
Food and water intake (A) and feeding efficiency (B) in GFAP-Cre Egfrflox/flox mice 
(N=6) and their control littermates (N=10) fed a WD. Results are expressed as mean ± 
SEM. Statistical significance: * P < 0.05 and *** P < 0.0001 vs. control.   
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Figure 16.  Effects of Egfr CNS deletion with GFAP-Cre on energy expenditure and 
activity.  
Caloric energy expenditure (A), oxygen consumption, (B), distance ran (C), and speed 
during running (D) in GFAP-Cre Egfrflox/flox mice (N=6) and their control littermates 
(N=10) fed a WD. Energy expenditure is in watts of caloric energy expended per kg of 
body weight.  Results are expressed as mean ± SEM. Statistical significance: *** P < 
0.0001 vs. control.   
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Figure 17. Effects of Egfr CNS deletion with GFAP-Cre on uncoupling proteins-1 and 3 
expression. 
Uncoupling protein-1 expression interscapular and epididymal fat (A) and uncoupling 
protein-3 expression in skeletal muscle (B) of control (N=10) and GFAP-Cre Egfrflox/flox 
(N=6) mice at 20 weeks of age fed the WD.  Results are mean ± standard error. 
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Figure 18. Effects of Egfr CNS deletion with GFAP-Cre on hypothalamic neuropeptide 
and Egfr expression levels. 
Results are from control (N=10) and GFAP-Cre Egfrflox/flox (N=6) mice at 20 weeks of 
age. Results are mean ± standard error.  Statistical significance: *P < 0.05 and **P < 0.01 
vs. control. 
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Figure 19. Representative inguinal fat pad histology from control and GFAP-Cre 
Egfrflox/flox mice. 
Control (A) and GFAP-Cre Egfrflox/flox mice (B) at 20 weeks of age. 7-10µm sections. 20x 
magnification. 
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Figure 20. Effects of Egfr CNS deletion on adipocyte-specific factors in epididymal fat 
pads. 
Results are from control (N=10) and GFAP-Cre Egfrflox/flox (N=6) mice at 20 weeks of 
age fed the WD. Results are mean ± standard error. Statistical significance: ** P < 0.01 
vs. control.  
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Figure 21.  Glucose tolerance test measurements from control and GFAP-Cre Egfrflox/flox 
mice. 
Results are from 20 week old control (N=10) and GFAP-Cre Egfrflox/flox (N=6) mice.  
Results are mean ± SEM. 
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Figure 22.  Average HOMA-IR measurements from control and GFAP-Cre Egfrflox/flox 
mice. 
Results are from 20 week old control (N=10) and GFAP-Cre Egfrflox/flox (N=6) mice.  
Results are mean ± SEM. * P < 0.05 vs. control. 
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CHAPTER 4 
THE EPIDERMAL GROWTH FACTOR RECEPTOR IS NOT REQUIRED IN 
ADIPOCYTES FOR ADIPOSE DEPOSITION BUT IS REQUIRED FOR 
NORMAL GROWTH IN MICE  
 
Melanie B. Weed,1 Tang-Cheng Lee,2 and David W. Threadgill1,2 
1Curriculum in Toxicology, University of North Carolina, Chapel Hill, North Carolina; 
2Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 
Abstract 
As a result of the worldwide rise in obesity and obesity-related complications 
such as diabetes, stroke, and cardiovascular disease, understanding the mechanisms 
associated with this disease and determining treatment options is necessary.  The 
epidermal growth factor receptor (EGFR) is involved in adipogenesis and therefore may 
contribute to the regulation of energy homeostasis.  Using a diet-induced obesity mouse 
model, we found that inhibition of EGFR either genetically with the Egfrwa2 hypomorphic 
allele or pharmacologically with a small molecule inhibitor against the EGFR tyrosine 
kinase (AG1478) slows adipose mass deposition.  Therefore, due to this adipose 
phenotype and to determine the role of EGFR in adipose deposition, we deleted Egfr 
specifically in adipocytes using the Egfrtm1Dwt conditional allele and the aP2-Cre 
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transgenic line.  Mice were fed a high-fat western diet over three months.  Body weight 
and MRI measurements were collected monthly and upon sacrifice, heart, liver, and 
adipose depots were dissected, weighed, and stored.  Ablation of EGFR within 
adipocytes showed no effect on adipose deposition.  However an overall increase in the 
growth rate of these animals was observed, possibly due to a compensatory mechanism 
through the insulin-like growth factor receptor.  
Introduction 
As a result of the worldwide rise in obesity and obesity-related complications 
such as diabetes, stroke, and cardiovascular disease, understanding the in vivo 
mechanisms associated with this disease and determining treatment options is necessary.  
Obesity is just one of the factors associated with metabolic syndrome, which includes 
such symptoms as hypertension, insulin resistance, and hyperlipidemia.  Metabolic 
syndrome is also associated with increased inflammatory responses such as cytokine and 
free fatty acid release (26, 27, 124, 125). Recent studies implicating a key role of the 
epidermal growth factor receptor (EGFR) in adipogenesis suggest activation of this 
signaling pathway may contribute to obesity. 
The EGFR and other ERBB family members are expressed in a wide range of 
tissues and cell types that regulate a number of cellular processes such as proliferation, 
differentiation, motility, apoptosis, and survival (1-4).  The ERBB family consists of four 
members: EGFR (ERBB1), ERBB2, ERBB3, and ERBB4 that all contain an extracellular 
ligand binding domain, a transmembrane region, and an intracellular tyrosine kinase 
domain.  Upon binding of ligands to the extracellular domain, these members form homo 
or heterodimers that initiate autophosphorylation of tyrosine residues and signaling 
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cascades (3-6).  We have previously shown that that male and female wild-type B6 mice 
chronically exposed to small molecule EGFR inhibitors and mice homozygous for the 
waved-2 (Egfrwa2) hypomorphic allele exhibit delayed weight gain over the course of 
exposure compared to controls, with the mass of other organs not affected (120).  
Therefore, we determined if EGFR signaling was important within adipocytes for adipose 
deposition.  We examined the molecular mechanisms underlying the reduction in adipose 
mass by modeling a typical high-fat western diet (WD) and analyzing the morphological 
and metabolic parameters associated with adipose deposition when Egfr is specifically 
deleted in adipocytes using the ap2-Cre transgenic mouse model.  We found that deleting 
EGFR within adipocytes did not result in an adipose phenotype; rather we found an 
increased growth rate in these animals compared to control littermates. 
Materials and Methods 
Animals and treatment.  aP2-Cre mice were mated with Egfrflox/+ or Egfrflox/flox 
mice.  ap2-Cre Egfrflox/flox male mice with their control littermates (ap2-Cre, ap2-
CreEgfrflox/+, Egfrflox/+, or Egfrflox/flox) were started on a high-fat western diet (WD) 
(Research Diets D12079B, New Brunswick, NJ, 40% calories from fat) at eight weeks of 
age for three months (113). The WD is nutritionally matched with the STD AIN-93G diet 
(Research Diets, D10012G) except for increased fat and reduced fiber, calcium, and 
vitamin D, more consistent with the diets consumed by people in North America.  Mice 
had free access to food and water throughout each study. Body weight and food and 
water intake measurements were collected at the start of the study and every week 
thereafter.  All mice were sacrificed according to an approved University of North 
Carolina (UNC) Institutional Animal Care and Use Committee’s protocol.  Inguinal, 
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epididymal, perirenal, and interscapular fat pads, heart, liver, and skeletal muscle were 
collected and stored at -80°C. 
Genotyping.  Genomic DNA was extracted from ear tissue using 25mM 
NAOH/0.2mM EDTA and 40mM Tris HCL for use in PCR reactions in all genotyping 
assays.  The Egfrflox allele was amplified using 1 uL DNA in each PCR reaction for 35 
cycles (30 s at 94°C, 1 min at 60°C, and 1 min at 72°C).  The primers were lox3s: 
5’CTTTGGAGAACCTGCAGATC-3’ and lox3as: 5’CTGCTACTGGCTCAAGTTTC-
3’. A 375 bp PCR product was detected from the Egfrflox allele and a 320 bp PCR product 
from the wild-type allele.  For the EgfrΔ allele, DNA was amplified for 40 cycles (30 s at 
94°C, 20 s at 60°C, and 20 s at 72°C).  The primers for this reaction were Delta-3: 
5’CTCAGCCAGATGAT-GTTGAC-3’ and Delta-4: 5’CCTCGTCTGTGGAAGA-
ACTA-3’ and a 129 bp PCR fragment was detected for the EgfrΔ allele.  For the aP2-Cre 
transgene, DNA was amplified for 38 cycles (30 s at 94°C, 1 min at 56°C, and 1 min at 
72°C) with primers CRE-1: 5’-GTGATGAGGTTCGCAAGAAC-3’ and CRE-2: 
5’AGCATTGCTGTCACTTGGTC-3’. A 278 bp PCR fragment was generated from the 
Cre transgene. All PCR products were run on a 3% agarose gel at 150mV for 25 minutes 
and all reactions used Taq DNA polymerase (Qiagen, Germantown, MD) and a 
GeneAmp PCR system 9700 (Applied Biosystems, Foster City, CA). 
MRI.  Body composition was collected by magnetic resonance imaging (MRI) 
(EchoMRI, Houston, TX) once a month starting at eight weeks of age for three months.  
Glucose Tolerance Test. Mice were fasted four hours prior to administration of 
the GTT. d-glucose (Sigma, St. Louis, MO) was dissolved in phosphate buffered saline 
and administered to mice via i.p. injection (2 g/kg). Samples of whole-blood (2–3 µl 
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each) were collected from a tail clip bleed immediately before and 15, 30, 60, 90, and 120 
minutes after glucose injection. Blood glucose levels were measured using a Freestyle 
Glucose Monitoring System (Abbott Laboratories, Abbott Park, IL). 
Homeostatic model assessment of insulin resistance. HOMA-IR calculations were 
performed using the HOMA Calculator 2.2.2 (University of Oxford, United Kingdom). 
Gene expression.  Total RNA was extracted from fat pads of control and aP2-Cre 
Egfrflox/flox mice using TRIzol (Invitrogen, Carlsbad, CA). 400 ng of total RNA was 
reverse transcribed using the AffinityScriptTM QPCR cDNA synthesis kit (Stratagene, La 
Jolla, CA).  The expression of insulin growth factor-1 (Igf1), IGF1 receptor (Igf1r), 
growth hormone receptor  (Ghr), insulin growth factor binding protein-3 (Igfbp3), leptin 
(lep), and tumor necrosis factor-α (Tnfa) were determined by real-time quantitative PCR 
(qPCR) using the Brilliant® II QPCR Master Mix (Stratagene) and Assays-on Demand 
primers and probes (Applied Biosystems).  Results are represented as mean fold changes 
relative to control groups. Reactions were run on a Stratagene MX3000P machine with 
analysis software. Threshold cycles (CT) were determined by an in-program algorithm 
assigning a fluorescence baseline based on readings prior to exponential amplification. 
Fold change in expression was calculated using the 2−ΔΔCt method (127), with 36B4 as the 
endogenous control. 
Blood Biochemical Analyses. Blood samples were collected at the beginning of 
the study and monthly thereafter by tail clip or terminal cardiac puncture.  Serum 
cholesterol and triglycerides were analyzed at UNC’s clinical chemistry core. Blood 
glucose levels were measured using a Freestyle Glucose Monitoring System (Abbott 
Laboratories).  Adipokine measurements including leptin, adiponectin, insulin, 
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plasminogen activator inhibitor-1 (PAI-1), and resistin were analyzed using a mouse 
serum adipokine kit (Linco Research, MADPK-71K, St. Charles, MI) and a BioRad 
Luminex Instrument (Austin, TX).  Serum IGF1 levels were analyzed by ELISA 
(Immunodiagnostic Systems, Scottsdale, AZ).   
Statistics.  Results are expressed as mean ± SEM.  Unpaired t-tests were used to 
determine statistical significance of these measurements between treated and control 
groups using Prism 4.0 (GraphPad).  Linear regression analysis for growth curves was 
also performed using Prism 4.0.  Group means were considered statistically significant at 
p < 0.05.   
Results 
aP2-Cre Egfrflox/flox mice grow faster than controls but do not have higher adiposity 
To investigate the role of EGFR within adipocytes, Egfr was deleted specifically 
in adipocytes by crossing loxP-flanked Egfr mice (Egfrflox/flox) (137) with transgenic mice 
expressing the Cre recombinase under control of the adipose fatty acid binding protein 
(aP2) promoter (138).  Cre expression was observed in adipose tissue, as expected, 
however deletion of EGFR in the liver is also noted (Figure 23A).  qPCR of EGFR 
mRNA expression in the liver however showed no change between groups (Figure 23B).  
Wild-type, Egfrflox/+, and aP2-Cre mice displayed similar phenotypes and therefore were 
considered as controls.  
ap2-Cre Egfrflox/flox mice displayed similar body and organ weights and fat and 
lean mass as their control littermates when fed a WD for three months (Figure 24).  Also, 
no differences in adipose cell number or area were observed between fat pads of control 
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and ap2-Cre Egfrflox/flox mice (data not shown), consistent with no changes in fat mass 
between groups.  However, ap2-Cre Egfrflox/flox mice did show a greater postnatal growth 
rate compared to their control littermates (Figure 25A) that was not due to an increase in 
fat mass (Figure 24A) or an increase in food intake (Figure 25B).   
Increased serum IGF1 levels in aP2-Cre Egfrflox/flox mice  
Given the observed growth phenotype, we investigated why deletion of EGFR 
specifically in adipocytes would cause an increase in overall growth rate.  The insulin 
growth factor (IGF)-1 receptor (IGF1R) is a tyrosine kinase receptor similar to EGFR and 
the insulin receptor that controls proliferation and differentiation in many tissues and 
cells when bound by its ligands.  IGF1 is structurally similar to insulin and increased 
IGF1 levels in the body lead to increased overall growth (154-156).  Therefore, we 
determined if the overall growth rate increase could be due to an increase in IGF1 levels.  
At eight weeks of age, IGF1 serum levels in aP2-Cre Egfrflox/flox mice were significantly 
greater than controls (Figure 26A).  However, we did not observe any changes in Igf1 or 
Igf1r mRNA expression in the epididymal fat pads or liver at sacrifice between these 
groups (Figure 26B; data not shown).  Also, there were no changes in mRNA expression 
of growth hormone receptor (Ghr) in the epididymal fat depot or liver (Figure 27) or 
Igfbp3 mRNA expression in this epididymal fat depot (data not shown). 
Deletion of Egfr in adipocytes causes a decrease in serum cholesterol levels 
To determine the metabolic consequences of Egfr deletion within adipocytes, 
cholesterol, triglyceride, glucose, and adipokine levels were analyzed in the blood and 
serum of these mice.  Expression levels of Tnfa and lep were also analyzed in epididymal 
fat pads.  A decrease in cholesterol levels in aP2-Cre Egfrflox/flox mice compared to 
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controls was observed however no other differences were noted between groups (Table 
6).  To test whether EGFR deletion within adipocytes is associated with changes in 
insulin resistance in a diet-induced obesity mouse model, we evaluated insulin sensitivity 
through measuring homeostasis model assessment of insulin resistance (HOMA-IR) and 
a glucose tolerance test (GTT).  There were not differences in intraperitoneal GTT or 
HOMA-IR between groups (Figure 28 and Figure 29, respectively). 
Discussion 
The EGFR and other ERBB receptors are expressed in a wide range of tissues and 
cell types that regulate a number of cellular processes such as proliferation, 
differentiation, motility, apoptosis, and survival (1-4).  From work performed in our and 
other labs, we know the EGFR has important functions in intestinal, heart, central 
nervous system, and placental development and EGFR deficient mice show pre- and 
postnatal lethality (120, 135, 157, 158).  It has also been shown that EGFR signaling 
plays a role in adipose deposition.  By increasing concentrations of EGF, a ligand to 
EGFR, an increase in adiposity of adult female mice and in 3T3-L1 mature adipocytes 
occurs by increasing triglyceride synthesis.  This effect is inhibited by treating these 
animals with either anti-EGF or by removing the submandibular gland from the mouse, 
which produces high levels of EGF (68-70), without changes in other organ weights.  Our 
lab observed a similar adipocyte-specific phenotype with the use of AG1478, an EGFR 
tyrosine kinase inhibitor, in the chow of male C57BL/6J mice.  We therefore 
hypothesized that EGFR signaling within adipocytes would be important for adipose 
deposition and deleted Egfr specifically within adipocytes to address this hypothesis.   
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To target adipocytes specifically, we obtained mice expressing Cre recombinase under 
the aP2 promoter.  The aP2 promoter is used in most adipose-specific inactivations being 
expressed highly in differentiated adipocytes; however, it is also expressed in 
macrophages and shows non-adipose tissue specificity in the embryo (88, 89, 159).  
EGFR expression was unaffected in most tissues of control animals, indicating that the 
modified EGFR locus with loxP or the transgene did not affect EGFR expression.  EGFR 
expression using PCR showed downregulation in the liver of control animals, however 
qPCR did not verify this on an mRNA level.  
aP2-Cre Egfrflox/flox mice were fertile and viable and expressed no differences in 
body weight, organ weights, or in adipocyte histology as compared to control littermates 
at 20 weeks of age.  Cholesterol levels were significantly lower in aP2-Cre Egfrflox/flox 
mice at 20 weeks of age, while no other metabolic consequences were noted between 
groups.  We do not see decreased fat mass with deletion of EGFR in adipocytes like we 
do in the whole animal downregulation of EGFR using AG1478.  This could be due to 
the differences in the timing of altered EGFR signaling.  Wild-type C57BL/6J mice were 
eight weeks of age when they were administered AG1478.  At this age these mice already 
posses preadipocytes and mature adipocytes with normal EGFR signaling.  With 
inhibition of EGFR, effects on both proliferation and differentiation of cells would occur 
challenging the normal development of adipose mass.  However, with the ap2-Cre 
model, EGFR is deleted from birth in cells that are programmed for adipocyte lineage, 
leaving pluripotent cells with normal EGFR signaling able to produce adipocytes.  Also, 
in these cells with decreased EGFR signaling, IGF1 may compensate for normal growth. 
Although we did not observe an adipose-related phenotype in aP2-Cre Egfrflox/flox 
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mice at 20 weeks of age, we did see one related to growth rate.  An increase in the growth 
rate of aP2-Cre Egfrflox/flox mice over controls was observed between eight and 20 weeks 
of age.  As noted previously, this increase in growth is not due to larger, heavier mice or 
to an increase in food intake.  To account for this increase in growth, other mechanisms 
may exist that compensate for downregulation of EGFR signaling within adipocytes.  
One such compensatory mechanism could be through the IGF1R pathway. 
The IGF1R is a tyrosine kinase receptor similar to EGFR and signaling through 
this receptor by its ligands (i.e., IGF1 and IGFII) controls proliferation and differentiation 
in many tissues and cell types.  Bioavailability of these ligands is through binding to 
IGFBPs, which bind IGFs locally or removes them from circulation (138, 154-156, 160).   
Increased IGF1 levels in circulation increase overall growth while a decrease in IGF1 
leads to growth retardation.  Tissue specific overproduction leads to only that tissue or 
organ growing larger, even with higher IGF1 in the serum (154, 161).  In this study, we 
do see increased IGF1 levels in the serum of aP2-Cre Egfrflox/flox mice at eight weeks of 
age.  This is similar to what was noted in a study with IGF1R deletion in adipocytes of 
mice using the aP2-Cre transgene.  These researchers observed an increase in serum 
IGF1 levels; however they also noted an overall increase in growth and fat pad weights, 
concluding that IGF1R in adipocytes was important in regulating serum IGF1 levels 
(138).  In our study however, we do not see an increase in fat pad weights at 20 weeks of 
age even with the increase in IGF1 serum levels.  
To establish potential causes for an increase in serum IGF1 levels, we determined 
mRNA expression levels of Igf1, Igf1r, and Ghr in the fat pads and liver of aP2-Cre 
Egfrflox/flox mice and their control littermates.  Egfr deletion within adipocytes caused no 
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changes in Igf1, Igf1r, or Ghr mRNA expression in adipose tissue or liver.  The liver 
produces and secretes IGF1 into the circulation (154).  Therefore, since there is no 
difference in Igf1 or Igf1r mRNA expression in liver, the systemic increase of IGF1 noted 
is not due to liver production.  This suggests that this increase is due to the production 
from the adipose tissue.  Others have abolished Igf1 from the liver using conditional gene 
targeting and observed low plasma IGF1 levels; however postnatal growth of these mice 
did not differ from controls, suggesting IGF1 is also generated by other tissues.  Also, 
IGF1 is necessary for differentiation in 3T3-L1 preadipocytes and to stimulate cellular 
growth and lipogenesis in differentiated adipocytes by acting in an autocrine/paracrine 
fashion (138, 155).  Presumably, local adipocyte production of IGF1 could then lead to 
an increase in serum IGF1 levels and an overall increased growth rate.  
The question as to why downregulation of EGFR signaling in adipocytes would 
lead to increased IGF1 serum levels and overall growth resides within the transactivation 
potential of EGFR.  EGFR is the point of convergence of growth signals from different 
stimuli such as G-protein coupled receptors, the IGF1R pathway, and cytokine receptors 
(155).  With regards to adipose development, both IGF1R and EGFR activate similar 
downstream signaling pathways such as MAPK for growth, and are required for 
preadipocyte proliferation and adipocyte differentiation (66, 163).  It has been suggested 
that crosstalk between EGFR and IGF1R is due to an autocrine mechanism of proteolytic 
cleavage of an EGFR ligand HBEGF in COS-7 cells that leads to signaling through the 
MAPK pathway (75, 164).  One study employed 3T3-L1 preadipocytes to decipher the 
relationship between the IGF1R and EGFR pathways in adipocyte differentiation.  Cells 
were treated with an EGFR tyrosine kinase inhibitor, AG1478, with or without EGF or 
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IGF1 ligands.  They found no inhibition of IGF1 stimulated MAPK activity, however 
there was inhibition of this pathway with EGF stimulation (66).  Therefore the IGF1 
receptor pathway does stimulate mitogenesis through MAPK signaling in this cell culture 
model and a compensatory mechanism could occur without EGFR as in the fat pads of 
the aP2-Cre Egfrflox/flox mice (156).   
In conclusion, deletion of EGFR in adipocytes using ap2-Cre results in an 
increased postnatal growth rate and lower cholesterol levels compared to controls with no 
changes in glucose homeostasis.  Autocrine/paracrine regulation of IGF1 may be 
occurring to produce the growth phenotype and the IGF1R pathway may be 
compensating for the lack of EGFR in adipocytes to produce normal adipose mass.  
Additional experiments will be needed to fully understand what is occurring in 
adipocytes and if there is indeed a compensatory mechanism due to downregulation of 
EGFR signaling in vivo since EGFR and IGF1R share many common pathways. 
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Parameter Control aP2-Cre Egfrflox/flox 
Cholesterol, mg/dL 240 162* 
Triglycerides, mg/dL 107 112 
Blood Glucose, mg/dL 186 194 
Leptin, ng/mL 21.7 ± 4.1 20.9 ± 3.7 
Leptin, fold change/control 1 ± 0.19 0.95 ± 0.12 
Insulin, ng/mL 2.52 ± 0.5  2.84 ± 0.3 
PAI-1, ng/mL 3.29 ± 0.7 3.60 ± 0.7 
Resistin, ng/mL 5.20 ± 0.7 4.75 ± 0.7 
TNFA, fold change/control 1 ± 0.47 1.24 ± 0.5 
Adiponectin, ng/mL 2.66 ± 0.06 2.08 ± 0.11 
 
Table 6. Serum and expression clinical data from control and aP2-Cre Egfrflox/flox mice.    
Results are from 20 week old control (N=12) and aP2-Cre Egfrflox/flox (N=10) mice fed a 
WD for 3 months.  Results are mean ± SEM.  Statistical significance: *P < 0.05 vs. 
control.          
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Figure 23.  PCR analysis of DNA and expression of EGFR in liver of control and aP2-
Cre Egfrflox/flox mice.   
(A) DNA from the epididymal fat depot (1) and liver (2) from aP2-Cre Egfrflox/flox (N=10) 
and in epididymal fat depot (3) and liver (4) from control mice (N=12). The EgfrΔ allele 
is the recombination between the loxP sites resulting in Egfr removal.  The wild-type 
allele is 320 bp, the Egfrflox allele is 375 bp, and EgfrΔ allele is 129 bp.  L= 1 kb ladder. 
(B) mRNA expression of EGFR in liver from control and aP2-Cre Egfrflox/flox mice. 
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Figure 24.  Effect of Egfr deletion with in adipocytes on organ weights fat mass.  
Magnetic Resonance Imaging (A), normalized fat pad/BW data (B) and normalized 
organs weight/BW data (C) from ap2-Cre Egfrflox/flox (N=10) mice and their control 
littermates (N=12) at 20 weeks of age.  Results are expressed as the mean ± SEM. 
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Figure 25.  Effect of adipocyte-specific Egfr deletion on growth and food intake.   
Growth rate (A) and food intake (B) from control (N=12) and aP2-Cre Egfrflox/flox (N=10) 
mice.  Eight week old mice were placed on a WD for 3 months.  Results are mean ± 
SEM.  Statistical significance: *** P < 0.001 vs. control. 
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Figure 26.  IGF1 serum levels and Igf1 mRNA expression levels in control and aP2-Cre 
Egfrflox/flox mice. 
IGF1 serum levels (8 weeks of age) (A) and  Igf1 mRNA expression levels (20 weeks of 
age) (B) in control (N=12) and aP2-Cre Egfrflox/flox (N=10) mice. Results are expressed as 
the mean ± SEM.  Statistical significance: *** P < 0.0001 vs. control.  
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Figure 27.  Effects of Egfr deletion in adipocytes on growth hormone receptor mRNA 
levels in epididymal fat depot and the liver.  
Results are from control (N=12) and aP2-Cre Egfrflox/flox (N=10) mice fed a WD. Results 
are mean ± SEM. 
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Figure 28. Glucose tolerance test measurements in control and aP2-Cre Egfrflox/flox mice.    
 
Results are from 20 week old control (N=12) and aP2-Cre Egfrflox/flox (N=10) mice fed a 
WD for 3 months.  Results are mean ± SEM. Statistical significance: *P < 0.05 vs. 
control. 
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Figure 29. Average HOMA-IR measurements from control and aP2-Cre Egfrflox/flox mice. 
Results are from 20 week old control (N=12) and aP2-Cre Egfrflox/flox (N=10) mice fed a 
WD for 3 months.  Results are mean ± SEM. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 The ERBB family is expressed in a wide range of tissues and cell types that 
regulate a number of cellular processes such as proliferation, differentiation, motility, 
apoptosis, and survival (1-4). Regulation of these signaling cascades is a complex 
process, with regards to duration and potency of activation, and aiding in the complexity 
is the different heterodimer combinations within the family and the transactivation 
potential by different mediators.  EGFR signaling in adipogenesis has been studied in 
vitro and in vivo, using cell lines already committed to the adipocyte lineage or by 
perturbing EGFR signaling with ligands to the receptor, respectively.  These studies 
revealed that peptides such as the growth factor EGF possesses both lipogenic and 
lipolytic effects; with increased amounts increasing adiposity in mature female mice and 
in 3T3-L1 mature adipocytes but decreasing adiposity when EGF is given to neonatal 
mice (62, 69, 71).  Also, Phase I clinical trials evaluating EGFR TKIs EKB-569 and 
gefinitib for tumors associated with EGFR pathway activation report grade 1/2 anorexia 
in approximately 20-30% of patients (166, 167).  Given these mechanisms of EGFR 
signaling in adiposity and anorexia, we explored the consequences of chronic EGFR 
inhibition in vivo.  This research is relevant and timely due to the overall rise in 
overweight and obesity over these past few decades and the need for understanding the 
underlying mechanisms for therapy.  Obesity drugs that block lipid absorption or increase 
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satiety signals have been generated, however side effects such as cardiovascular 
complications and gastrointestinal effects may limit their usage (104, 108-110).  
We have previously shown that female wild-type B6 mice chronically exposed to 
small molecule EGFR inhibitors exhibit decreased weight gain over the course of 
exposure compared to controls, with no signs of toxicity (120).  Others have also 
observed in vivo this adipocyte-specific decrease in weight with inhibition of EGF, with 
no effect on other organ weights (68, 69, 120, 121).   Therefore, our first experiment 
sought to determine the mechanisms behind this phenotype by characterizing the 
metabolic and developmental consequences of EGFR inhibition in diet-induced obesity 
models.  Using both genetic and pharmacological models of EGFR inhibition in vivo, we 
found a decrease in body weight and fat mass due to decreases in food intake and feeding 
efficiency, along with smaller adipocytes within fat depots and an overall improved 
clinical profile compared to control littermates.  However, no differences in RER, caloric 
energy expenditure, activity, or thermogenesis were observed between groups.  Next we 
wanted to determine the mechanisms for this decrease in food intake and feeding 
efficiency with fat mass reduction.  Since energy balance depends on the regulation of a 
peripheral system sensing satiety and energy storage and the CNS using these signals to 
regulate homeostasis (90, 91), we ablated EGFR within the periphery (intestinal 
epithelium and adipocytes) and in the CNS using the Egfrtm1Dwt conditional allele and the 
Villin-Cre, aP2-Cre, and GFAP-Cre, transgenic lines, respectively and fed these animals 
a high-fat diet.  Ablation of EGFR within the intestinal epithelium and adipocytes showed 
no effect on adipose deposition, however an overall increase in the growth rate of aP2-
Cre Egfrflox/flox animals was observed.  Deletion specifically within the CNS caused a 
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significant reduction in body weight and adipose mass, similar to the phenotype noted in 
the previous experiments.  Therefore, we evaluated the metabolic, histological, and 
clinical consequences of this phenotype.   Similar to the B6 mice fed the WD with an 
EGFR inhibitor (WD/INH), a decrease in feeding efficiency, smaller adipocytes per fat 
depot, improved clinical chemistry, and no differences in wheel running or RER were 
observed in GFAP-Cre Egfrflox/flox mice compared to controls.  However, an increase in 
food intake, caloric energy expenditure, and oxygen consumption were noted in these 
animals, contrasting the B6 DIO model.  We next evaluated hypothalamic neuropeptides 
NPY and POMC to determine mechanisms for this alteration in feeding and energy.  We 
found decreases in anorexigenic neuropeptide Pomc mRNA expression in GFAP-Cre 
Egfrflox/flox mice.  We also observed a decrease in hypothalamic Egfr mRNA expression in 
these mice, suggesting that EGFR downregulation in the hypothalamus is partly 
responsible for the metabolic phenotype observed.  We also evaluated transcript levels of 
adipocyte stage-specific factors within the fat depots of each group and found increased 
Arb3 mRNA expression and a trend for increased Ucp1 mRNA expression in the GFAP-
Cre Egfrflox/flox mice.  This suggests that increased energy expenditure from hyperphagia, 
hyperkinesia, thermogenesis, and adipocyte oxidation is involved in the reduced body 
weight observed in these GFAP-Cre Egfrflox/flox mice. 
In vivo studies of obesity have determined that, along with alterations in feeding, 
increases in energy expenditure, measured by home cage activity, body temperature, and 
increased brown adipocytes within white adipose depots, account for the observed weight 
loss (150, 168).  To better evaluate reasons for the weight loss noted with EGFR 
inhibition, pair-fed experiments and those relating to the above mentioned mechanisms 
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should be performed, on both the B6 DIO mouse model and the GFAP-Cre Egfrflox/flox 
mice and their control littermates.  If EGFR inhibition is to be used as a potential therapy 
for obesity, the use of an inhibitor is more relevant.  However, examining the specific 
CNS effect with EGFR deletion is also useful.  First, in order to distinguish the effects of 
caloric intake on the AG1478-induced fat mass decrease, pair fed experiments where 
control animals are fed the same amount of chow consumed by the animals fed the 
WD/INH should be performed.   If the pair-fed animals show a higher fat mass compared 
to the WD/INH fed group this could indicate that the anti-obesity effects of EGFR 
inhibition are not only due to suppression of feeding, but some other effect such as 
energy expenditure, further evidenced by the decrease in feeding efficiency in both 
models.   
Conventional treatment of obesity includes weight loss through reduced caloric 
intake and increasing physical activity (38, 48).  In our studies, mice with EGFR 
inhibition or CNS ablation showed less body weight and fat mass, however their activity 
measured by voluntary wheel running was not different between groups.  In GFAP-Cre 
Egfrflox/flox mice, increased oxygen consumption was also noted, evidence of potential 
increased home cage activity. Wheel running may or may not be a direct reflection of 
home cage activity in mice fed a HFD since some studies show increased home cage 
activity with increased wheel running while others show no change in home cage activity 
but decreases in wheel running (130-132).  Therefore, analyzing their locomoter home 
cage activity may provide evidence of increased energy expenditure associated with 
EGFR downregulation.  To determine this, locomoter activity should be assessed by 
placing individual animals into open-field boxes equipped with infrared beams to monitor 
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activity throughout the study.  Increased locomoter activity with reductions in body fat 
has been observed in both obese Zucker and DIO rats, supporting that increased 
locomoter activity would translate into increased energy expenditure and loss of body fat 
(168).  Also interesting would be to determine if body temperature differed between 
groups since it has been observed in other DIO animal models that a higher rectal 
temperature is related to weight loss (150, 169).  Another measure of increased energy 
expenditure is to evaluate evidence for increased thermogenic brown fat within white 
adipose depots.  Although B6 mice fed WD/INH did not show increased Ucp1 expression 
in epididymal fat pads, GFAP-Cre transgenic mice showed a trend for increased Ucp1, 
suggesting increased brown adipocytes in this white adipose depot.  However, since 
perirenal, inguinal, and other subcutaneous white adipose depots possess more capacity 
for brown adipocytes than this visceral depot, we should analyze the other fat depots 
collected for brown adipocytes and Ucp1 expression (139, 140).  Increased Ucp1 
expression in the other fat pads of these animals would then suggest more brown 
adipocytes in the white adipose tissue.  Promotion of brown fat adipogenesis in these 
depots could therefore contribute to increased thermogenesis and the decreased fat mass 
observed. Therefore, enhanced energy expenditure may represent a peripheral mechanism 
contributing to weight loss in the form of increased locomoter activity, rectal 
temperature, and/or increased brown adipocytes within white adipose tissue in B6 mice 
fed WD/INH or in the GFAP-Cre Egfrflox/flox mice.   
From the data collected in this study and other studies, it seems that an increase in 
fatty acid oxidation within white adipocytes may be another mechanism whereby GFAP-
Cre Egfrflox/flox mice have lower fat mass than their control littermates. This phenotype 
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has been observed in mice that overexpress a triglyceride hydrolase in white adipose 
tissue or are treated with an orexigenic melanin-concentrating hormone-1 receptor 
antagonist.  In both of these models, increased lipolysis is specific to white adipose tissue 
without increased circulating levels of fatty acids (148-150).  The fatty acids liberated 
from white adipose depots could have detrimental effects on metabolism by causing 
ectopic lipid storage in liver, skeletal muscle, heart, and other organs and therefore where 
these fatty acids are going needs to still be determined in these models.  Increased 
delivery of fatty acids to the liver would affect metabolism through alterations in glucose 
production, lipoprotein secretion, and insulin clearance.  Also, increased lipid in skeletal 
muscle could decrease insulin-stimulated peripheral glucose disposal (147, 170).  Excess 
lipid in the heart can also lead to adverse alterations in cardiac function (157).  First, to 
evaluate if lipolysis is occurring in the fat depots of these animals, adipose tissue explants 
should be collected from both WD/INH and GFAP-Cre Egfrflox/flox mice and their control 
littermates and glycerol release measured in culture.  Higher glycerol amounts would 
indicate higher lipolysis in the adipose depots.  Next, expression of lipid metabolism 
genes in the white adipose tissue and the liver of these mice should be assessed to provide 
for further evidence that increased oxidation is occurring leading to a lower weight loss.  
Determining the levels of fatty acids in serum and in organs such as the liver, heart, and 
skeletal muscle should also be performed to assess if an increased oxidation in adipose 
tissue lead to increases in circulating lipid or in ectopic lipid storage in GFAP-Cre 
Egfrflox/flox mice compared to their control littermates.  We demonstrate that excreted fat is 
not different in GFAP-Cre Egfrflox/flox mice compared to their control littermates, therefore 
some evidence that circulating fatty acids may not be increased.    
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Ultimately, the question as to how this decrease in Egfr within the hypothalamus 
alters neuropeptide expression and how these alterations signal to the periphery for 
decreased body weight and perhaps increased fatty acid oxidation remains.  Perhaps 
EGFR in the hypothalamus is affecting lipid oxidation activity within the ARC, which is 
sensed by appetite or energy homeostatic neurons to alter food intake and energy 
signaling to the periphery.  This has been noted in studies of an inhibitor to fatty acid 
synthase in the hypothalamus (151).  Decreased body weight was observed, which was 
due in part to the inhibitor altering AMP-activated protein kinase (AMPK) activity, a 
sensor of peripheral energy balance within the hypothalamus (151).  Future studies could 
look at AG1478’s effect on AMPK levels in neuronal cultures and determine if activity is 
altered thereby demonstrating a link between the hypothalamus and the periphery with 
EGFR deletion using GFAP-Cre.   
Although both the DIO B6 model and the GFAP-Cre transgenic model produced 
fat mass reductions the genetic model is phenotypically more severe.  The opposite 
feeding behavior and alterations in hypothalamic neuropeptides noted between these two 
models imply that this effect is due to CNS alternations. To better determine the 
mechanism of these phenotypes, we first need to understand why behavior changes are 
occurring in our animals with AG178 treatment or EGFR deletion with GFAP-Cre.   To 
assess changes in behavior relating to diet or treatment, microarray technology is often 
employed (172, 173).  This same technique could be applied to our study to evaluate the 
effects of AG1478 administration or EGFR deletion with GFAP-Cre in the 
hypothalamus, where central appetite regulatory genes are enriched; validating changes 
of gene expression levels using quantitative RT-PCR.  Altered expression of genes in the 
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hypothalamus of mice fed the WD/INH or GFAP-Cre Egfrflox/flox mice might therefore be 
understood as the underlying mechanism behind the phenotypes observed.  Also, this 
analysis could confirm or deny the role of EGFR in the hypothalamus in appetite and 
energy homeostasis.  Altered genes could include those involved in lipid metabolism, 
glucose homeostasis, satiety, or inflammation. 
Off-targets effects have been observed in female wild-type B6 mice chronically 
exposed to small molecule EGFR inhibitors with decreased weight gain compared to 
controls.  No significant differences were observed in wet heart weight or cardiomyocyte 
size in these animals.  However, histological analysis revealed an increase in fibrosis and 
decreased expression of an anti-apoptotic gene in these hearts (120).  Although the wet 
weights of hearts in the B6 mice fed the WD/INH or GFAP-Cre genetic studies did not 
differ between groups, heart histology should be performed to evaluate these findings.    
Given the complexity of EGFR signaling and heterodimers that occur between 
family members, perhaps alterations of other family members are also involved in the 
decreased fat mass phenotype.   Microarrays performed on the hypothalamuses of the 
animals may provide evidence of their involvement.  ERBB2 does not bind a ligand and 
therefore heterodimerization with other ERBB members is required, with EGFR being 
the preferred partner (72, 75).  ERBB2 expression increases during the proliferation and 
growth arrest phases of adipogenesis.  However, progression through differentiation leads 
to a decrease in expression, similar to EGFR.  When serum-starved 3T3-L1 cells are 
treated with EGF, an increase in ERBB2 activation is noted showing that EGF could 
activate ERBB2 in these cells through heterodimerization with EGFR (72, 75).  Although 
AG1478 is a tyrosine kinase inhibitor that is highly selective for EGFR (IC50, 3 nM 
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EGFR versus > 100 µM ERBB2) (2, 5, 119), EGFR and ERBB2 have a high sequence 
homology in their catalytic domains and therefore AG1478 could suppress the activity of 
both receptors (158).  To determine if AG1478 is suppressing ERBB2 in this model, 
ERBB2 expression could be assessed in the fat pads of the B6 mice fed the WD/INH and 
their control littermates.  To further evaluate the potential role of ERBB2 in weight loss 
phenotypes, similar experiments with wild-type B6 mice could be performed with an 
ERBB2 selective inhibitor or the Cre/loxP system could be utilized for hypothalamic-
specific deletion.   With respect to ERBB3 and ERBB4 and their role in the body weight 
phenotype, both are expressed in the hypothalamus (144) and experiments with their 
deletion in this region or with inhibitors could be performed.  Our lab has generated mice 
with a conditional brain deletion of ERBB3 (ERBB3tm2Dwt) using the Nestin-Cre 
transgene (Nestin-Cre Erbb3flox/flox).  Male mice were placed on normal chow at six 
months of age and Nestin-Cre Erbb3flox/flox mice weighed significantly less than their 
wild-type littermates at the study’s end.  However, our lab has assessed the brain 
phenotype in Nestin-Cre Egfrflox/flox mice and found neurodegeneration and growth 
retardation similar to what is found in Egfr null mice (138).  Therefore this decreased 
weight may not be directly due to ERBB3’s effects on feeding and energy, but rather on 
neuronal survival. 
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